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ABSTRACT
DESIGN AND SYNTHESIS OF A NEW CLASS
OF SELF-CROSS-LINKED POLYMER NANOGELS
MAY 2011
SIRIPORN JIWPANICH
B.Sc., CHULALONGKORN UNIVERSITY
M.Sc., CHULALONGKORN UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sankaran Thayumanavan
The design and engineering of nanoscopic drug delivery vehicles that stably
encapsulate lipophilic drug molecules, transport their loaded cargo to specific target sites,
and release their payload in a controlled manner are of great interest in therapeutic
applications, especially for cancer chemotherapy. This dissertation focuses on chemically
cross-linked, water-soluble polymer nanoparticles, termed nanogels, which constitute a
promising scaffold and offer the potential to circumvent encapsulation stability issues. A
facile synthetic method for a new class of self-cross-linked polymer nanogels,
synthesized by an intra/intermolecular disulfide cross-linking reaction in aqueous media,
is described here. This simple emulsion-free method affords noncovalent lipophilic guest
encapsulation and surface functionalization that may allow for targeted delivery. The
encapsulation stability of lipophilic molecules sequestered within these nanoscopic
containers is evaluated by a fluorescent resonance energy transfer (FRET) based method
developed by our research group. We demonstrate that the encapsulation stability of

vii

noncovalently encapsulated guest molecules in disulfide cross-linked polymer nanogels
can be tuned and that guest release can be achieved in response to a biologically relevant
stimulus (GSH). In addition, varied hydrophobicity in the self-cross-linked nanogels
affects the lipophilic loading capacity and encapsulation stability. We reveal that optimal
loading capacity is limited by encapsulation stability, where over-loading of lipophilic
molecules in the nanoscopic containers may cause undersirable leakage and severely
compromise the viability of such systems for drug delivery and other biological
applications.
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CHAPTER 1
INTRODUCTION
The engineering and manufacturing of materials at the atomic and molecular
scale, so called “nanotechnology” are of great interest for several applications,
especially nanomedicine.(Allen and Culis 2004; Wagner, Dullaart et al. 2006)
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy
bringing new hope to patients. This technology can be applied to drugs that are poorly
water-soluble and therefore cannot be administered via the preferred route, or in some
cases, at all.
Among the current cancer therapies, including surgical intervention, radiation
and chemotherapeutic drugs, chemotherapy seems to be the primary method for cancer
treatment. However, the bioavailability of these drugs is limited due to their
hydrophobicity which requires a specific mode of delivery and higher doses. Moreover,
lack of control and specific targeting of these drugs often kills healthy cells and causes
toxicity to the patient. Therefore, the development of a nanoscale targeting approach is
required for delivery of chemotherapeutic agents which can selectively accumulate at
the target tumor site. In this chapter, we briefly review the class of nanoscopic targeting
drug delivery vehicles, particulary for cancer therapy, in term of structural design for
lipophilic drug encapsulation and release.

1.1 Passive and Active Targeting Drug Delivery
Targeting mechanisms can be broadly classified into two categories, viz. active
and passive. Passive targeting is based on the propensity of nanoscopic objects of 10-
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200 nm size to extravasate into solid tumor tissues and prevent lymphatic drainage, the
so-called enhanced permeation and retension (EPR) effect (Figure 1.1).(Matsumura and
Maeda 1986) Early clinical data has shown that therapeutic nanoparticles can enhance
efficacy in terms of improving pharmacokinetic and pharmacodynamics profiles,
reducing side effects, and targeting for specific diseases.(Peer, Karp et al. 2007; Davis,
Chen et al. 2008; Lee, Song et al. 2010) Thus the development of nanoparticles gains
more attention, particularly for drug delivery applications which account for threequarters of all research activities and the nanomedicine market, especially in cancer
chemotherapy.(Wagner, Dullaart et al. 2006; Farokhzad and Langer 2009)

Figure 1.1: Cartoon represention of passive and active targeting mechanisms.
Although the passive targeting approach is the primary mechanism for
chemotherapeutic delivery, there are still some limitations. One is that the drug may not
diffuse efficiently and the random nature of the approach makes it difficult to control
the drug uptake pathway. This may cause multiple-drug resistance (MDR), a situation
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where the chemotherapy treatments fail due to the resistance of cancer cells towards one
or more drugs.(Gottesman, Fojo et al. 2002; Ferrari 2005; Peer and Margalit 2006)
MDR occurs because integral membrane proteins, known as MDR transporters,
overexpressed on the surface of cancer cells can expel drugs from the cells which cause
a lowering in the therapeutic effect and thus the cancer cells soon develop resistance to
a variety of drugs.(Gottesman, Fojo et al. 2002)
An alternative route to achieve cancer drug delivery and avoid the MDR effect
is to engineer the nanocarriers in such a way that they have specific binding to the
tumor cell surfaces which can facilite the internalization of nanocontainers and
diffusion of the drug into cancer cells. This can be accomplished by conjugating
nanocontainers, with encapsulated cancer therapeutics, to specific ligands that are
complementary to the receptors overexpressed on a tumor cell surface, so called active
targeting approach (Figure 1.1). These targeting ligands enable nanoparticles to bind
specifically to cell-surface receptors and can enter cells by receptor-mediated
endocytosis before the drug is released. Recent works comparing non-targeting and
targeting nanoparticles have shown that targeted ligands play an important role in the
enhancement of cellular uptake into cancer cells.(Torchilin 2005; Bartlett, Su et al.
2007; Peer, Karp et al. 2007) For example, folate receptor-mediated cell uptake of
doxorubicin-loaded liposomes into an MDR cell line has shown to be unaffected by Pglycoprotein (Pgp)-mediated drug efflux.(Goren, Horowitz et al. 2000)

1.2 Nanoscopic Drug Delivery
Nanoscopic drug delivery vehicles are nanosized materials, with 10-200 nm
diameters, that can carry lipophilic drugs and release them at a specific target site. Since

3

the small molecule chemotherapeutics are water-insoluble and highly toxic due to the
indiscriminate access to both healthy and cancerous cells, the versatile nanoscopic drug
delivery vehicles, an alternative route to administer these drugs, should exhibit a few
key characteristics: (i) the delivery vehicle should have a desirable and tunable particle
size for the EPR effect; (ii) the nanocontainers should be able to incorporate lipophilic
drug molecules and enhance the the aqueous solubility of these drugs; (iii) the
nanocarriers should prevent the drug from degradation processes and premature release
before they reach the target tumor site; (iv) the effective delivery vehicles should be
able to cross biological barriers and release the drug into the tumor cells.(Davis, Chen et
al. 2008)
To date there have been some nanoscopic drug delivery vehicles which are
clinically approved and several more that are under clinical investigation and
development.(Peer, Karp et al. 2007) In this chapter, we briefly review the family of
nanocarriers including polymer-lipophilic drug conjuagates, metallic nanoparticles,
dendrimers, liposomes, micelles, and polymeric cross-linked nonoparticles or nanogels.

1.2.1 Polymer-Drug Conjugates
The polymer-conjugated anticancer drug concept was introduced by Ringsdorf
in 1975.(Ringsdorf 1975) This was considered the beginning of an era for the
development of polymer therapeutics. Polymer-drug conjugates consist of a
biocompatible polymeric carrier with attached low-molecular weight biologically active
molecules through a bioresponsive or cleavable linker. By using this method, not only
can a drug be covalently linked to the polymer backbone, but also a targeting ligand can
be attached, as a guiding agent, onto the same polymer as shown in Figure 1.2. The
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release of the drug can be achieved by triggering the appropriate linkers which can
respond to changes in the physical and biological environments, such as temperature,
pH, and the presence of enzymes or proteins at the target site.(Rodrigues, Beyer et al.
1999; Gillies, Goodwin et al. 2004; Kim, Gil et al. 2006; Schmid, Chung et al. 2007;
York, Kirkland et al. 2008; Liu, Maheshwari et al. 2009; Miller, Erez et al. 2009) The
polymer-drug conjugates have become a fast-growing field because they have
demonstrated several advantages over the corresponding parent drugs by (i) enhancing
the solubility of hydrophobic drugs; (ii) enhancing therapeutic efficacy; (iii) reducing
the toxicity; and (iv) increasing plasma half-life and volume distribution.(Li and wallace
2008)

Figure 1.2: Cartoon representation of polymer-drug conjugates.
Early studies on polymer-drug conjugates by Duncan, Kopecek, and Ringdorf in
the late 1970s resulted in the first polymer-drug conjugates to be used for medical
treatment.(Duncan; Duncan and Kopecek 1984; Duncan 2006) Polymer-protein
conjugates are the first practical use of polymer therapeutics as anticancer agents.
SMANCS, a conjugate consisting of the anti-tumor protein neocarzinostatin (NCS)
covalently linked to two styrene maleic anhydride (SMA) polymer chains(Iwai, Meada
et al. 1984; Duncan 2006) and a PEGylated protein was introduced into clinical trial in
the early 1990s.(Davis 2002; Duncan 2003; Harris and Chess 2003) To date, polymer-
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protein conjugates are used routinely as anticancer therapeutics as an adjunct to
chemotherapy.(Duncan 2003) Currently, more than 14 polymer-drug conjugates are in
Phase I or II clinical trials, for example, anti-endothelial immunoconjugates, fusion
proteins, and caplostatin, the first polymer-angiogenesis inhibitor conjugate.(Arap,
Pasqualini et al. 1998; Schraa, Kok et al. 2002; Satchi-Fainaro, Puder et al. 2004; Peer,
Karp et al. 2007; Sanchis, Canal et al. 2010)
Among these, the most advanced conjugate is Opaxio® (poly-L-glutamic acidpaclitaxel conjugate (PG-TXL)), formerly known as Xyotax® from Cell Therapeutics
Inc., which is expected to reach the market in the near future.(Li and wallace 2008) In
PG-TXL, paclitaxel is conjugated to a synthetic poly(L-glutamic acid) through its 2’hydroxyl group via an ester linkage (Chart 1.1). The resulting conjugate is highly water
soluble (>20mg/kg) and has demonstrated significant enhanced antitumor efficacy and
improved safety compared with paclitaxel in preclinical studies.(Li and wallace 2008)

Chart 1.1: Structures of polymer-drug conjugates: a) Opaxio®; b) PK2.
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HPMA copolymer-doxorubicin (Dox)-galctosamine conjugate, PK2, is the only
polymer-drug conjugate based on active targeting (Chart 1.1). PK2 is a 27 kDa HMPA
copolymer derivatized with 6.5% mol/wt, <2% free doxorubicin, and 2% mol/wt
galactose, with efficient targeting of the asialoglycoprotein receptor selectively
expressed on hepatocytes and in hepatomas.(Li and wallace 2008)
Nonetheless, the polymer-drug conjugates often have different pharmacokinetic
profiles from the parent drugs, and are thus considered new chemical entities
(NCEs).(Peer, Karp et al. 2007) Although there are a variety of novel drug targets and
sophisticated chemistries available, only four drugs (doxorubicin, camptothecin,
paclitaxel, and palatinate) and four polymers (N-(2-hydroxylpropyl)methacrylamide
(HPMA) copolymer, poly-L-glutamic acid, poly(ethylene glycol) (PEG), and Dextran)
have been repeatedly used to develop polymer-drug conjugates.(Duncan 2003; Peer,
Karp et al. 2007) This is because significant chemistry is needed to develop an
appropriate linker between the drug and the polymer backbone that can be cleaved to
release the drug molecules. Another barrier is the limit of the loading capacity due to
the lipophilic drug molecules attached to the polymer chain which dictate the carrier
solubility.

1.2.2 Metallic Nanoparticles
Metallic nanoparticles are of great interest for nanoscopic drug delivery due to
the fact that their sizes are controlled by the metal core, affording their production with
near monodisperisty (Figure 1.3).(Peer, Karp et al. 2007) The surface of the metal core
can be tailored by incorporating desired functionalities or ligands to facilitate the active
targeting mechanism. Metallic nanoparticles, particularly gold nanoparticles have
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recently been developed for cancer drug delivery.(Duncan, Kim et al. 2010) Some metal
nanoparticles have been used for magnetic resonance imaging providing an opportunity
to design nanocarriers which have both imaging and therapy characteristics.

Figure 1.3: Cartoon representation of metallic nanoparticle.
Hydrophobic drugs can be loaded onto metallic nanoparticles through noncovalent interactions or covalent conjugation to the particles via cleavabale linkages
similar to those described in the polymer-drug conjugation systems. The encapsulation
of lipophilic drugs into the monolayer of the metallic nanoparticle can be achieved by
the incorporation of appropriate ligands on the metal shell to provide hydrophobic
interaction between the drug and ligands. Rotello et al. have reported a biocompatible
gold nanoparticle with a 2.5 nm core modified with an alkanethiol interior and a
tetra(ethylene glycol) (TEG) hydrophilic shell for cancer drug delivery.(Kim, Ghosh et
al. 2009)
However, inorganic nanoparticles may not provide advantages over other types
of nanoscopic drug deliveries for systemic targeting of individual cancer cells because
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they are not biodegradable or small enough to be cleared easily, resulting in potential
accumulation in the body, which may cause long-term toxicity. In addition, the drug
molecules attached to the surface of the particles or loaded onto their monolayer surface
limit the solubility of the drug-loaded scaffolds in aqueous media, as these drugs are
lipophilic and surface functionalities dictate the solubility of these metallic
nanoparticles.

1.2.3 Dendrimers
Dendrimers are synthetic, branched macromolecules that form a tree-like
structure with well-controlled structural architecture that show promise in several
biomedical applications.(Fréchet and Tomalia 2001) Dendrimers are considered as a
new class of polymers having been first published in the late 1970s and early
1980s.(Buhleier, Wehner et al. 1978; Newkome, Yao et al. 1985; Tomalia, Dewald et
al. 1985) A dendrimer is composed of focal point or core, branches or intermedediate
layers, and surface groups or the periphery as shown in Figure1.4. Since dendrimer
synthesis can be achieved in a stepwise fashion, they are theoretically monodisperse in
size and highly reproducible. These characteristics make dendrimers interesting
candidates for drug delivery scaffolds because they should also provide reproducible
pharmacokinetic behavior.(Newkome, Yao et al. 1985; Tomalia, Dewald et al. 1985;
Hawker and Fréchet 1990; de Brabander-van den Berg and Meijer 1993) Traditional
polymer systheses result in polymers which are polydisperse making the
pharmacokinetics of these polymers varied and lack control and reproducibility.
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Figure 1.4: Cartoon representation of dendrimer structure.
There are several classes of dendrimers that have been reported for biological
applications, e.g. polyamidoamines, polyamines, polyamides (polypeptides), poly(aryl
ethers), polyesters, carbohydrates, and DNA.(Lee, MacKay et al. 2005) Amongst these
scafolds, polyamidoamine (PAMAM) dendrimers, structure shown in Chart 1.2, are
commercially available with a variety of generations and peripheral functionalities and
are the most widely used dendrimer scaffolds for biological applications. However, they
exhibit significant toxicity due their multiple cationic amine groups at the scaffold
surface. To date, there are several classes of dendrimers that have been developed
which are highly biocompatible and water soluble.(Gillies and Fréchet 2005)
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Chart 1.2: Structure of polyamidoamine (PAMAM) dendrimers.
Initial studies of dendrimers, as potential drug delivery scaffolds, focused on
their use as unimolecular micelles for noncovalent encapsulation of drug molecules.
Because of their highly branched structures at high molecular weighs, they show
nanometer size scaffolds which are globular in shape and provide a pocket for
hydrophobic molecule encapsulation. The advantage of unimolecular micelles is that
their micelle structure is maintained at all concentrations (no CMC). However, it is
difficult to control the release of the drugs and they have less encapsulation stability.
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Figure 1.5: Cartoon representation of dendrimers as drug delivery scaffolds:
a) unimoleculear micelle; b) drug conjugated; c) self-immolative.
An alternative approach to the development of dendrimers as drug delivery
containers is to covalently link the drug molecules to the dendrimer scaffold. The
stepwise syntheses of dendrimers provide scaffolds with a well-defined number of
peripheral groups. The controlled multivalency of dendrimers can be used to attach
several drug molecules, targeting groups, and solubilizing groups to the periphery in a
well-controlled manner. The release of the drug can be controlled by incorporating
degradable linkages between the drug molecule and dendrimers. For example, cisplatin,
a potent anticancer drug with nonspecific toxicity and poor water solubility, was
attached to the periphery of a G-4 carboxylate-terminated PAMAM dendrimer.(Malik,
Evagorou et al. 1999) The dendrimer-drug conjugates show increased solubility,
decreased systematic toxicity, and selective accumulation in solid tumor.
12
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methotrexate.(Kukowska-Latallo, Candido et al. 2005) The amine groups at the
periphery of G-5 PAMAM dendrimers were modified with acetyl groups to reduce their
surface charge. The actylated PAMAM was subsequently functionalized with folate, as
a target ligand, fluorescein fluorophore, and methotrexate. In vivo delivery of
dendrimer-methotrexate conjugates, using multivalent targeting, results in a tenfold
reduction in tumor size compared with that achieved with the same molar concentration
of free systemic methotrexate.(Kukowska-Latallo, Candido et al. 2005; Hong, Leroueil
et al. 2007) This work provided motivation for further pre-clinical development, and a
variety of dendrimers are now under investigation for cancer treatment.
Recently, degradable dendrimers known as self-immolative, cascade-release or
geometrically disassembling dendrimers have been reported. In these dendrimers, a
single chemical reaction at their core or periphery initiates their complete
depolymerization into small, structurally similar units.(Amir, Pessah et al. 2003; de
Groot, Albrecht et al. 2003; Li, Szalai et al. 2003; Szalai, Kevwitch et al. 2003) This
intelligent structural design could be a potential candidate for future delivery vehicles.
However, dendrimers are expensive and require complex synthetic methods
which will bring difficulties for large-scale production. The unique properties of
dendrimers could be useful in practical term, but the optimization of structure and
properties to maximize drug bioavailability and targeting to the tumor cell need to be
improved and further investigated.
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1.2.4 Liposomes
Liposomes, nanosized lipid vesicles, first described in the 1960s, are another
nanoscopic drug delivery vehicle that has shown significant promise in drug delivery
technology.(Bangham, Standish et al. 1965; Gabizon 2001; Gabizon 2001; Torchilin
2005) This is because of their components which comprise of natural substances that
are biocompatible, biodegradable and nontoxic. Liposomes consist of lipid bilayers with
a size of ~100 nm and larger (Figure 1.6). Liposomes carrying chemotherapeutic smallmolecule drugs have been approved for cancer treatment since the mid-1990s.(Peer,
Karp et al. 2007) However, since liposomes have hydrophilic interiors, these assemblies
are primarily used for hydrophilic drug molecules. For example, the water-soluble salt
of Dox has been successfully formulated with liposomes (e.g. Doxil).(Safra, Muggia et
al. 2000; Bao, Goin et al. 2004) In addition, liposomes do not provide controlled release
capability and have low circulation time due to phagocytosis, a process by which
phagocytes remove foreign materials.(Torchilin 2005; Peer, Karp et al. 2007)

Figure 1.6: Cartoon representation of liposomes.
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Cell specific targeting of liposomes was first described in 1980 and the first
improved long circulating liposomes were described in 1987 and later named “Stealth
liposomes”.(Leserman, Barbet et al. 1980; Allen and Chonn 1987) Poly(ethylene
glycol) (PEG) was first introduced in the early 1990s to modify the surface of liposomes
for improved pharmacokinetics (PK) after intravenous (i.v.) administration.
Subsequently, the use of polyethylene glycol (PEG) was shown to increase circulation
times for liposomes.(Klibanov, Maruyama et al. 1990) However, the long circulation
time of liposomes may cause extravasation of the drug in unexpected sites and lead to
severe side effects. Palmar-plantar erythrodysesthesia (PPE), also called the hand-foot
syndrome, is a dermatologic toxicity reaction seen with high doses of many types of
chemotherapy. It is the most common clinical side effect from the PEGylated liposomal
doxorubicin.(Peer, Karp et al. 2007)
Although chemotherapeutic drugs formulated with liposomes make up most of
the primary delivery systems on the market, the lack of controlled release properties of
encapsulated drugs, fast oxidation of some phospholipids, and high production cost
need to be improved. Additionally, the liposome interior is not suitalble for
encapsulating lipophilic molecules.

1.2.5 Micelles
Polymeric micelles (5-100 nm) have been of great interest as a versatile
nanomedicene platform, especially for cancer therapeutic applications due to their
ability to encapsulate poorly water-soluble chemotherapeutic agents in their lipophilic
interior.(Kataoka, Harada et al. 2001; Torchilin 2004; Sutton, Nasongkla et al. 2007;
Kale, Klaikherd et al. 2009) Micelles consist of self-assembling small molecule
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surfactants or amphiphilic polymers exibiting phase separatation between hydrophobic
and hydrophilic segments to form nanoscopic supramolecular core/shell structures
(Figure1.7). Its hydrophobic core provides lipophilic drug encapsulation, while the
hydrophilic shell provides solubility in aqueous media. Currently, five micellar
formulations for anticancer therapy are under clinical evalulation, of which GenexolPM has been FDA approved for use in patients with breast cancer. An early phase of
clinical trials has shown that the cancer drug-polymer micelle formulation can enhance
the aqueous solubility and prolong their in vivo half-lives with lessened systemic
toxicity.(Oerlemans, Bult et al. 2010) Free doxorubicin (Dox) has an elimination phase
half-life (t1/2, β), or physiological excretion half-life, of 48 min, while the polymer
micelle formulation has roughly triple the half-life, bringing it in the range of 2.32.8h.(Sutton, Nasongkla et al. 2007)

Figure 1.7: Cartoon representation of micelles.
Though, micellar assemblies formed from small molecule surfactants have
inherent stability issues. Small molecule surfactants can assemble to form micelles
when the concentration is above the critical micelle concentration (CMC). The
assemblies formed from amphiphilic block copolymers tend to exhibit enhanced
stabilities.(Gu, Zhang et al. 2008) In the late 1980s, Kazunori Kataoka and Alexander
16

Kabanov independently developed the used of block copolymer micelles for drug
delivery. To date several micellar formulations of anticancer agents are in clinical trials.
However, these still face significant complications because of a requisite concentration
for assembly formation.

This drastically limits the practicality of in vivo micelle

utilization, as large dilution of injected micelles into the body can destabilize these selfassembling systems, causing undesirable release of the encapsulated drug payload
before arrival at the target site.(Bae and Yin 2008) Moreover, the interaction between
micelles and biological components, such as cellular membranes and blood
components, can lead to release of the cargo from the micelle core at undesirable
locations.(Chen, Kim et al. 2008; Chen, Kim et al. 2008) Therefore, alternate strategies
are required to overcome such premature release.

1.2.6 Cross-Linked Polymer Nanoparticles
Cross-linked polymer nanoparticles or nanogels have recently been introduced
as an alternative class of nanoscopic drug delivery vehicles.(Oh, Drumright et al. 2008;
Kabanov and Vinogradov 2009; Vinogradov 2010) Recent studies suggest that nanogels
are very promising for future biomedical applications due to their tunable chemical and
three-dimensional (3D) physical structure, good mechanical properties, high water
content, and biocompatibility. Nanogels are nanosized hydrogel networks that disperse
in aqueous solution and are composed of hydrophilic or amphiphilic polymer matrices
that are cross-linked by a physical or chemical cross-linking agent (Figure
1.8).(Kabanov and Vinogradov 2009) Like hydrogels, nanogels are three-dimensional
(3D) biocompatible material with high water content. These 3D structures allow the
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entrapment of large amount of bioactive molecules with high encapsulation stability in
their networks.(Jiwpanich, Ryu et al. 2010)

Figure 1.8: Cartoon representation of nanogels and the mechanism of drug release.
The polymeric cross-linked nanoparticles, first introduced by Sunamoto et al. in
1993, were nanosized swollen aggregates of cholesterol-modified polysaccharide
(pullulan) for delivery of insulin.(Akiyoshi, deguchi et al. 1993) Nonetheless, the term
“nanogel” was first introduced by Kabanov and Vinogradov to define cross-linked
bifunctional networks of cationic and neutral polymers such as the branched PEG-crosslinked-PEI made from polyethylenenimine (PEI) and poly(ethylene glycol) (PEG) for
delivery of polynucleotides.(Vinogradov, Bronich et al. 2002; Kabanov and Vinogradov
2009)
Nanogels are very promising in drug delivery applications due to their large
loading capacity with high encapsulation stability and responsiveness to environment
factors, for example, ionic strength, pH, temperature, and the presence of enzymes or
proteins.(Kabanov and Vinogradov 2009) Loading of biological agents can be achieved
by electrostatic, van der Waals and/or hydrophobic interactions between the
encapsulated agents and the polymer matrix. As a result, the nanogels collapse forming
stable nanoparticles, in which biological/drug compounds are entrapped. In addition, the
large surface area of nanogels can be tailored with targeting ligands to enhance active
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targeted nanocarrier characteristics. In order to control the release of therapeutics over a
desired period of time, as well as enable the removal of the empty device after drug
release, (bio)degradable linkages such as esters, peptides, acetals, disulfides, and
hydrazones can be introduced into cross-linked networks.(Kabanov and Vinogradov
2009; Oh, Bencherif et al. 2009)
Although the early developments of nanogels were aimed at the transport of
biomacromolecules, recently significant progress has been reported for the delivery of
small therapeutic agents. For example, N-hexylcarbamoyl-5-fluorouracil, an anticancer
prodrug of 5-fluorouracil (5-FU), encapsulated in poly(N-isopropylacrylamide)-copoly(N-vinylpyrrolidone) (PNIPAAm/VP) nanogels coated with polysorbate 80 showed
enhanced therapeutic efficacy against parasites as well as reduced hepatotoxicity and
nephrotoxicity compared to the free drug.(Tyagi, Lala et al. 2005; Soni, Babber et al.
2006)
Since nanogels are relatively new to the area of nanoscopic drug delivery, the
synthetic methodologies for their preparation still need to be developed. The classical
preparations, microemulsion and inverse microemulsion methods, do not facilitate the
nanogels to be both water-soluble and encapsulate lipophilic guest molecules
simultaneously.(Oh, Siegwart et al. 2007; Oh, Tang et al. 2007; Bachelder, Beaudette et
al. 2008; Sisson, Steinhiber et al. 2009; Ryu, Jiwpanich et al. 2010) Furthermore,
present and future nanogel applications require a high degree of control over several
properties. These properties include stability for prolonged circulation in the blood
stream, novel functionality for further bioconjugation, controlled particle size with
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uniform diameter, and biodegradability for sustained release of the drug for a desired
period of time and facile removal of empty devices.

1.3 Summary and Dissertation Overview
In this chapter, we have discussed the classical nanoscopic drug delivery
vehicles for cancer therapy using their nanosize characteristics to transport lipophilic
drugs through cancer cells by passive targeting through EPR effect. The drug-loaded
nanoscopic carriers we described above can be classified into two categories: covalent
incorporation of drugs onto nanoscale scaffolds and noncovalent encapsulation of drugs
into nanoscale assemblies. To avoid the modification of parent drugs, which can alter
their therapeutic properties, we focus on the noncovalent encapsulation approach. We
have also discussed the cross-linked nanoscopic carriers which provide high
encapsulation stability and are considered promising nanoscopic drug delivery vehicles.
This dissertation describes a new class of self-cross-linked polymer nanogels as
promising nanoscopic drug delivery vehicles for noncovalent encapsulation of
lipophilic drugs. A methodology for the preparation of self-cross-linked nanogels is
described in Chapter 2. Since the cross-linked polymeric nanoparticles could provide
high encapsulation stability over classical supramolecular nanoassemblies, we describe,
in Chapter 3, a method development to track the noncovalent encapsulation stability
using FRET based methods. In Chapter 4, we detail the tuning of encapsulation stability
at maximum loading capacity of lipophilic molecules into self-cross-linked nanogels,
and Chapter 5 contains general conclusions and future research directions.
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CHAPTER 2
SELF-CROSS-LINKED POLYMER NANOGELS: A SURFACTANT-FREE
HYDROPHOBIC ENCAPSULATION METHOD
2.1 Introduction
Noncovalently encapsulating hydrophobic guest molecules in a water-soluble
container and then releasing them in response to a specific trigger are important goals in
supramolecular chemistry, carrying clear implications in applications such as drug
delivery.(Jeong, Bae et al. 1997; Allen and Culis 2004; Haag 2004; Koo, Rubinstein et
al. 2005; Lee, MacKay et al. 2005; Peer, Karp et al. 2007; Bachelder, Beaudette et al.
2008; Oh, Drumright et al. 2008; Kale, Klaikherd et al. 2009) When execution of these
supramolecular events is based on a nanosized host, there is even greater interest
because of the potential for passive targeting of tumor tissue through the enhanced
permeability and retention effect (EPR).(Baban and Seymour 1998; Maeda, Wu et al.
2000; Duncan 2003; Gillies and Fréchet 2005)
Chemically cross-linked, water-soluble polymer nanoparticles constitute a
promising scaffold in therapeutic delivery applications, offering potential to circumvent
stability issue.(Kakizawa, Harada et al. 1999; Aliyar, Hamilton et al. 2005; Oh,
Drumright et al. 2008; Fang, Zhang et al. 2009; Kabanov and Vinogradov 2009)
However, these polymeric nanoparticles or nanogels face cetain complications, as they
are prepared by microemulsion or inverse microemulsion methods.(Talsma, Eabensee et
al. 2006; Bachelder, Beaudette et al. 2008; Oh, Drumright et al. 2008; Sisson,
Steinhiber et al. 2009) Microemulsion methods, which involve oil-in-water emulsion,
utilize lipophilic monomers to produce the nanogels, which are thus generally water
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insoluble.

When

a

water-soluble

polymer

nanoparticle

is

desired,

inverse

microemulsion based synthesis is the preferable method. Note that the continuous phase
in the inverse microemulsion (water-in-oil) method is based on a lipophilic solvent and
therefore cannot be used to encapsulate hydrophobic guest molecules during
nanoparticle formation. Moreover, these methods are relatively complex and require
multiple purification steps to remove not only the unreacted monomer, but also the
surfactant materials that were used as the emulsion stabilizer. An attractive alternative
to forming polymer nanoparticles is to collapse a limited number of polymer chains.
Such methods have been previously reported, but require ultrahigh dilution conditions
or inverse addition conditions,(Kadlubowski, Grobelny et al. 2003; Jiang and
Thayumanavan 2005) which limit capabilities for guest molecule incorporation. To
overcome these issues, we develop a facile method that allows for the design and
syntheses of water-soluble polymer nanoparticles under non-emulsion conditions with
high lipophilic encapsulation capabilities.
A facile method, reported by us recently, allows for the design and syntheses of
polymer nanoparticles under non-emulsion condition.(Ryu, Chacko et al. 2010; Ryu,
Jiwpanich et al. 2010) The versatility of these polymer nanoparticles has been further
demonstrated by showing that (i) lipophilic guests can be easily incorporated
noncovalently within the nanoparticles; (ii) the noncovalently encapsulated guest
molecules can be released in response to a biologically relevant stimulus; and (iii) the
surfaces of these particles are functionalizable. For a stimuli-responsive functional
group, we considered a disulfide bond, since these bonds are susceptible to biochemical
reductants such as glutathione (GSH), thioredoxin, and peroxiredoxin.(Bernkop-
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Schnürch 2005; Heffernan and Murthy 2009) We have previously reported a synthetic
methodology in which a pyridyl disulfide (PDS) side chain functionality was used as a
handle for incorporating thiol-based functional groups onto polymers.(Ghosh, Basu et
al. 2006) The basis for this methodology is the higher reactivity of the pyridyl disulfide
bonds with thiols as compared to other disulfide functionalities, which is facilitated by
the release of a stable 2-thiopyridone byproduct. We envisioned taking advantage of
this high reactivity of the PDS functionality to affect cross-linking in polymer chains.
Our hypothesis involves the addition of a deficient amount of dithiothreitol (DTT),
which is known to cleave PDS bonds with great efficiency. When a deficient amount of
DTT is added, a corresponding small percentage of PDS groups will be converted to
free thiols. These free thiols would then react with an equivalent amount of the
remaining PDS functionalities to create disulfide bonds, which would effectively crosslink the polymer chains, independent of whether the process is intra-chain or interchain. We further envisioned that because the PDS functionalities are relatively
hydrophobic, they would collapse in the aqueous phase. If this were the case, we
hypothesized that polymer nanoparticles would be obtained upon treatment of our
polymers with deficient amount of DTT, without the need for ultrahigh dilution
preparative conditions (Figure 2.1). We also envisaged that the hydrophobic interior in
the aggregate would provide an opportunity to encapsulate lipophilic guest molecules
prior to cross-linking.
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Figure 2.1: Design and synthesis of the self-cross-linked polymer nanogels.
2.2 Results and Discussion
2.2.1 Design and Synthesis
The polymer nanogel precursor is based on a random copolymer that contains
oligoethyleneglycol (OEG) units and pyridyldisulfide (PDS) groups as side chain
functionalities. The role of the OEG unit is to introduce a charge-neutral hydrophilic
functional group, which is known to endow biocompatibility. The PDS functionality
plays several key roles: (i) this is a lipophilic functionality and thus plays a critical role
in providing a supramolecular amphiphilic nanoassembly in the aqueous phase. Note
that this feature avoids the use of any additional surfactant molecules to generate the
nanogel and the size of this nanoassembly dictates the size of the final polymer nanogel;
(ii) the amphiphilic nature of the assembly and lipophilic environment afforded by the
PDS functionality provides the opportunity for lipophilic guest molecules to be
sequestered within these nanoassemblies prior to cross-linking. (iii) The PDS
functionality is reactive, but specific to thiols and thus provides a mild method for
disulfide cross-linking to form the nanogel. (iv) Since the nanogels are based on
disulfide cross-linkers that can be cleaved by thiol-disulfide exchange reactions, these
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nanogels also provide a pathway to trigger the release of the stably encapsulated guest
molecules in response to an external stimulus.
Random co-polymer 1, containing 30% of the oligoethyleneglycol methacrylate
and 70% of the PDS-derived methacrylate, was prepared by reversible additionfragmentation chain transfer (RAFT) polymerization. Structures of the nanogel
precursors, polymer nanogels and synthetic approach are shown in Scheme 2.1.
The next step involves the conversion of these polymeric aggregates into
chemically cross-linked nanogels.

We hypothesized the formation of the nanogel

through the following process. Addition of a deficient amount of dithiothreitol (DTT)
would cause the cleavage of a well-defined percentage of the PDS groups to the
corresponding thiol functionalities. These thiol functionalities will then react within the
polymeric aggregates with unreacted PDS functionalities.

This reaction results in

disulfide cross-links within the polymeric aggregates causing the formation of the
nanogels, as shown in Scheme 2.1.
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Scheme 2.1: Structures of the polymers and nanogels. (i) Cleavage of specific amount
of PDS groups by DTT. (ii) Nanogel formation by inter/intrachain cross-linking. (iii)
Surface modification of nanogels with thiol-modified Tat peptide or FITC.
Cross-linked particles were synthesized from this polymer by adding 20 mol%
of DTT with respect to the number of PDS functionalities in the polymer. Note that
there would be residual PDS functionalities in these gels, providing useful handles for
introducing ligands on the nanogel surfaces (vide infra). We characterized the structures
obtained from these reactions by transmission electron microscopy (TEM) and dynamic
light scattering (DLS). DLS studies reveal that the structures obtained are ~190 nm in
size (Figure 2.2a). TEM images shown in Figure 2.2b revealed well-defined spherical
structures with slightly smaller diameters than those observed in DLS, which is
attributed to the possible swelling of the nanoparticles in water.

33

Figure 2.2: Size distribution of the nanogel (1 mg/mL) in water. (a) DLS trace. (b)
TEM image.
We were interested in identifying whether the obtained particle is indeed a stable
cross-linked structure and if the size of the particle is completely controlled by the size
of a polymer aggregate obtained prior to the cross-linking reaction. For this purpose, we
analyzed the size of the polymer assembly prior to the DTT reaction. DLS studies
revealed aggregates of about 17 nm, which suggests that the particles obtained upon
DTT reaction involved inter-chain cross-linking in addition to the possible intra-chain
reactions. We presume that this assembly is due to the amphiphilic nature of the
polymer caused by the hydrophobic PDS groups, because there were no discernible
nanoassemblies when acetone alone is used as the solvent (Figure 2.3). We can control
the size of the nanoparticle by varying the reaction conditions. In water, DTT cleavage
and disulfide exchange reactions occurred intramolecularly in polymer aggregates and
resulted in 10 nm size nanoparticles. Interestingly, after the formation of the polymer
nanoparticle using the DTT reaction, the size of the assemblies in both acetone and
water were identical (Figure 2.3). This illustrates the stability of the assembly and also
confirms that they are formed by chemical cross-linking of the functionalities. We
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calculated the water content of the nanogels based on the difference in size of the

nanogels in swollen and dried state. The average size of swollen gels in water measured
by DLS, and dried gels measured by TEM are 190 nm and 110 nm, respectively.
Therefore, from the difference in volume between dry state and swollen state in one
particle (7.0×105 nm3 and 3.5×106 nm3 for dried state and swelled state, respectively),
we can estimate that 2.8 ×106 nm3 volume is filled with water.

Figure 2.3: (a) Size distribution of polymers (black line) and nanoparticles prepared in
water (green line) and nanogels prepared in water/acetone (red line). The concentrations
are 1 mg mL-1 measured in water. (b) DLS of nanogel (1 mg mL-1) in water and acetone
showed almost same size distribution.
With our methodology, we were able to obtain two very different particle sizes
by simply varying the concentration of polymers. We analyzed the sizes of polymer
assemblies prior to the DTT reaction. DLS studies revealed aggregates of about 120 nm
at 10 mg/mL in water, and 12 nm below 5 mg/mL. Subsequent cross-linking reaction by
DTT led to nanoparticles with two different sizes (16 nm and 190 nm with 5 mg/mL
and 10 mg/mL, respectively) as shown in Figure 2.4. Upon decreasing the concentration
of copolymer 1 to below 0.5 wt% in water, we obtained 16 nm nanoparicles after DTT
induced cross-linking. The resulting nanoparticles showed the same size (190 nm) when
the solution was diluted ten times, while the polymer 1 at this concentration showed 12
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nm size. This once again confirms that the obtained particles are indeed stably crosslinked structures. This suggests that we can control the size of the nanoparticles by
simply tuning the reaction conditions.

Figure 2.4: (a) Time correlation function and (b) size distribution of co-polymer 1 at
different concentration (0.5 wt% and 1.0 wt%). (c) Time correlation function and (d)
size distribution of nanogels which were prepared at different concentration (0.5 wt%
and 1.0 wt%).
2.2.2 Guest Encapsulation and Triggered/Controlled Release
For a nanocarrier to be effective, it should be able to stably encapsulate
lipophilic guest molecules and release its contents in response to a biologically relevant
trigger.(Murthy, Thng et al. 2002; Jiang, Qi et al. 2007; Oh, Siegwart et al. 2007; Chan,
Wong et al. 2008; Zhang, Liu et al. 2008) Disulfide bonds are particularly attractive as
stimulus-sensitive functionalities in medicinal chemistry as they can be cleaved in the
presence of high reducing agent concentrations. Reducing agents, such as reduced
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glutathione (GSH), thioredoxin, and peroxiredoxin, are found at varying levels
throughout the body. For example, GSH is found in millimolar concentrations in the
cytosol, where as the extracellular concentration is only micromolar.(Bernkop-Schnürch
2005; Yang, Chen et al. 2006; Chong, Chandrawati et al. 2009; Sivakumar, Bansal et al.
2009) Therefore, a GSH-sensitive delivery vehicle can be effective in facilitating
specific intracellular delivery of encapsulated molecules.(Wu and Senter 2005; Li,
Lokitz et al. 2006; Bae, Mok et al. 2008; Jia, Wong et al. 2008; Bauhuber, Hozsa et al.
2009; Li, Zhu et al. 2009)

Figure 2.5: (a) Absorption spectra of pyridothione byproduct during nanogel synthesis.
(b) Size distribution of nanogels (1 mg/mL) in DLS.
We hypothesized that GSH could induce the release of loaded dyes through
cleavage of the disulfide cross-linking bonds and that the release kinetics could be tuned
by the cross-linking density in the nanogel. To test this possibility, we prepared three
different cross-linked particles by adding 10, 20 or 50 mol% (against the precursor PDS
groups) of DTT to polymer 1. The progress of the reaction was conveniently monitored
by tracking the release of the pyridothione byproduct through its characteristic
absorption at 343 nm. Considering the mechanism by which this addition results in
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cross-linked polymer particles and the percentage of PDS functionalities in polymer 1,
this reaction should result in nanoparticles NG1, NG2, and NG3 with 7%, 14%, and
35% cross-linking densities respectively, assuming 100% reaction efficiency. Our
estimations, based on pyridothione release, indicate that the actual cross-linking
densities correspond to 6%, 13%, and 25% respectively (Figure 2.5a). DLS studies
reveal that the structures obtained are all about 190 nm in size (Figure 2.5b).

Figure 2.6: TEM images of NG1 (a), NG2 (b), and NG3 (c).
TEM images reveal well-defined spherical structures with slightly smaller
diameters than those observed in DLS, which is attributed to the possible swelling of
the nanoparticles in water (Figure 2.6). It is interesting to note that the sizes of all three
nanogels are very similar. This suggests that the size of the assembly prior to the crosslinking reaction dictates the nanogel size and that further cross-linking occurs within
that nanoassembly.
To investigate the possibility of encapsulating hydrophobic guest molecules
within the interiors of these nanogels, we carried out the DTT-based cross-linking
reaction in the presence of Nile red, a hydrophobic dye. Nile red is inherently insoluble
in water. Therefore, the reaction was optimized using acetone as a solvent in the first
steps before the addition of water during the cross-linking reaction. Isolation of the
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nanoparticles and their subsequent dissolution in water retains Nile red, as discerned by
the emission spectra of all three gels (Figure 2.7).

Figure 2.7: The emission spectra of Nile red sequestered in polymer nanogels.
To explore triggered release, we added GSH into nanogel solutions and
investigated the release of Nile red by tracing the decrease in the hydrophobic dye’s
spectral emission intensity caused by its insolubility in the aqueous media. To examine
the GSH-dependent dye release, Nile red loaded nanogel solutions (0.05 wt%) in pH 7.4
sodium acetate buffer solution were treated with different concentrations of GSH (10
μM and 10 mM) and the intensity of Nile red emission at 610 nm was monitored for
three days.
At low GSH concentrations (10 μM), little dye release was observed for all
nanogels (Figure 2.8a-c). This concentration corresponds to that commonly observed
outside the cell and within the blood plasma. In contrast, high concentrations of GSH
(10 mM), corresponding to those found inside the cell, induced significant dye release
(Figure 2.8d-f).
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Figure 2.8: Dye release from the nanogels NG1 (a, d, g), NG2 (b, e, f), and NG3 (c, f, i)
(0.05 wt%) in response to varied GSH concentrations. (a-c) 10 μM GSH and (d-f) 10
mM GSH at pH 7.4, and (g-i) 10 mM GSH at pH 5. The release only occurred at high
GSH concentration. At acidic pH under 10 mM GSH, the release was faster and more
gradual over time than those at neutral pH.
Cross-linking density is most likely to influence the rate of dye release from the
nanogel interior. NG1 (6% cross-linked nanogel) showed rapid release reaching a
plateau after 6 h at 10 mM GSH in pH 7.4 buffer solution. NG2 (13% cross-linked
nanogel) showed slower release, reaching a maximum at 12 h; NG3 (25% cross-linked
nanogel) displayed gradual, highly sustained release for several days. Because the
cellular entry of these nanogels would likely involve endocytosis, we were interested in
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analyzing the release profile at lower pH. We found that the difference in the release
profile of these nanogels under acidic conditions (pH 5) is very similar to that observed
with pH 7 (Figure 2.8g-i). While this bodes well for endocytosis based entry into the
cells, we also found the release profile at high GSH concentration to be surprising, as
GSH activity is considered most efficient at neutral pH.(Moskaug, Sandvig et al. 1987)
As shown in Figure 2.9, similar release profiles were observed for all three gels over
several hours at both pH 5 and 7.4, clearly demonstrating that the kinetics of guest
release can be controlled by cross-linking densities. Nonetheless, we observed faster
release of encapsulated dyes in NG1 and NG2 at pH5, while there were no significant
different in NG3. We hypothesize that the remaining of PDS groups in NG1 and NG2
are protonated creating charge-charge repulsions that swell the nanogel networks. The
swelling of nanogels in acidic condition results in accelerating the rate of guest release.

Figure 2.9: (a) Comparison of GSH-induced dye release rate from the nanogels which
have different cross-linking densities at (a) pH 7.4 and (b) pH 5.
2.2.3 Cytotoxicity
We anticipated that our gels would be relatively non-toxic, because they are
made from biocompatible oligoethyleneglycol components as surface displays in a
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methacrylate backbone. Treatment of cells with the nanogels indeed allows high cell
viability and no concentration-dependent toxicity up to a nanogel concentration of 1 mg
mL-1 (Figure 2.10). This result indicates that the nanogel material is non-toxic and thus
a potential candidate for biological applications.
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Figure 2.10: In vitro toxicity of empty nanogels with 293T cells after 24 hour
incubation.
2.2.4 Surface Functionalization
We were also interested in testing our hypothesis that we can achieve surface
functionalization of these nanogels by thiol-disulfide exchange reactions with the
unreacted PDS groups. These PDS groups can be reacted with thiol-containing
compounds, allowing for chemoselective ligand modification. To test this, nanogel
solutions (1 mg mL-1) were treated with either excess fluorescein isothiocyanate (FITC)
or thiol-modified FITC (1 mg mL-1). Figure 2.11 shows a significant difference between
the two samples; while thiol-modified FITC treated nanogels exhibited very strong
fluorescein emission, the bare FITC treated nanogels solution showed very little
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emission, suggesting that the nanogels were covalently functionalized with thiolmodified FITC by disulfide linkage and that the observed fluorescence is not due to
noncovalent surface binding of the dye molecules.

Figure 2.11: The emission spectra of nanogels (1mg/mL) treated with thiol-modified
FITC (FITC-SH) and FITC.
To further investigate surface modification possibilities, nanogel solutions (0.1
mg mL-1) containing the hydrophobic dye, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI), were treated with a modified cell penetrating peptide,
Tat-SH (0.1 mg mL-1) with a C-terminal cysteine, for 24 h. These solutions were then
incubated with MCF-7 human breast cancer cell lines for just 2 h. The cell
internalization efficiency of the unmodified nanogels (control) and Tat-SH treated
nanogels were then examined by confocal microscopy.

43

Figure 2.12: Representative confocal microscopy images of MCF-7 cells incubated
with; (a) the unmodified nanogels, (b)Tat-SH treated nanogels.
As shown in Figure 2.12, the internalization of Tat-SH modified nanogels
occurred much more readily than that observed with the control gels, confirming the
effectiveness of using the remaining PDS groups to simply modify the nanogel surface.
This presents a clear method for incorporating ligands onto the polymer nanoparticles
and thus achieves specificity to pathogenic cells using chemoselective disulfide
chemistry.

2.3 Summary
We have demonstrated a simple, emulsion free method for the preparation of
biocompatible nanogels that provides the ability to encapsulate hydrophobic guest
molecules using intra/intermolecular disulfide formation of PDS containing polymers.
Since disulfide bonds are biodegradable in a reducing environment, these nanoparticles
hold great potential as intracelluar drug delivery vehicles. The release of guest
molecules can be induced by external stimuli. By varying the cross-linking density of
the nanogels, the release kinetics of guest molecules can be controlled. Additionally, we
have demonstrated that the surface of these nanoparticles can be efficiently
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functionalized under mild conditions. Taken together, the nanogel formation using the
self-cross-linking polymers and corresponding method of surface modification open a
new avenue for enhanced cytosolic drug delivery and establish a novel approach to
creating polymer nanogels for a range of biomedical applications from drug delivery to
biosensing.

2.4 Experimental
2.4.1 General Methods and Procedure
2,2′-Dithiodipyridine, 2-mercaptoethanol, polyethylene glycol monomethyl
ether methacrylate (MW 450), D,L-dithiothreitol (DTT), 1,1'-dioctadecyl-3,3,3',3'tetramethyl-indocarbocyanine perchlorate (DiI), Nile red, Tat-SH, and other
conventional reagents were obtained from commercial sources and were used as
received unless otherwise mentioned. Polymer was synthesized with RAFT
polymerization and then purified by precipitation with ethyl ether. S-dodecyl-S’-2-(2,2dimethylacetic acid) trithiocarbonate (CTA) and pyridyl disulfide ethyl methacrylate
(PDSEMA) were prepared using a previously reported procedures.(Lai, Filla et al.
2002; Ghosh, Basu et al. 2006) 1H-NMR spectra were recorded on a 400 MHz Bruker
NMR spectrometer using the residual proton resonance of the solvent as the internal
standard. Molecular weights of the polymers were estimated by gel permeation
chromatography (GPC) using PMMA standards with a refractive index detector.
Dynamic light scattering (DLS) measurements were performed using a Malvern
Nanozetasizer. The fluorescence spectra were obtained from a JASCO FP-6500
spectrofluorimeter. Transmission electron microscopy (TEM) images were taken using
a JEOL 100CX at 100 KV.
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Synthesis of pyridyl disulfide ethyl alcohol:

Aldrithiol-2 ( 20 g, 91 mol) was dissolved in 2.5 mL of methanol and then
glacial acetic acid (1 mL) was added to the solution. To this mixture, a solution of
mercaptoethanol (7.8 g, 99 mmol) in methanol (150 mL) was added drop-wise at
ambient temperature with continuous stirring. After, the reaction mixture was stirring at
room temperature for additional 3 hours, solvent was removed to get the yellow oil
crude product which was purified by flash column chromatography by using silica gel
as stationary phase and mixture of ethyl acetate:hexane (40:60) to afford the desired
product as colorless oil. Yield: 68 % 1H NMR (400 MHz, CDCl3) δ 8.54 (m, 1H, a),
7.63 (m, 1H, b), 7.42 (m, 1H,c), 7.18 (m, 1H, d), 3.83 (t, 2H, e), 2.97 (t, 2H, f).
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Synthesis of pyridyl disulfide ethyl methacrylate:

Pyridyl disulfide ethyl alcohol (11 g, 59 mmol) in dichloromethane (250 mL)
was added triethylamine (8.3 g, 82 mmol), and then the mixture was cooled in an icebath. To this cold mixture, a solution of methacryloyl chloride (8.6 g, 82 mmol) was
added drop-wise with continuous stirring. After the mixture was stirring at ambient
temperature for 6 hours, the mixture solution was extracted with water and wash with
brine. The organic layer was collected, dried over anhydrous Na2SO4 and concentrated.
The yellow oil crude product was purified by column chromatography using silica gel
and mixture of ethyl acetate:hexane (20:80). Yield: 66% 1H NMR (400 MHz, CDCl3) δ
8.47 (m, 1H, a), 7.63 (m, 2H, b), 7.08 (m, 1H,c), 6.12 (d, 1H, d), 5.58 (d, 1H, e), 4.39 (t,
2H, f), 3.08 (t, 2H, g), 1.93 (s, 3H, h).

13

C NMR (100 MHz, CDCl3) δ 167.1, 159.8,

149.7, 137.1, 136.0, 126.1, 120.9, 119.8, 62.4, 37.4, 18.3.
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Synthesis of random copolymer (1):

A mixture of S-dodecyl-S’-2-(2,2-dimethylacetic acid) trithiocarbonate (CTA)
(90 mg, 0.3 mmol), PDSEMA (5 g, 20 mmol), polyethylene glycol monomethyl ether
methacrylate (4 g, 8 mmol) and AIBN (10 mg, 0.06 mmol) were dissolved in DMF (10
mL) and degassed by performing three freeze-pump-thaw cycles. The reaction mixture
was sealed and then put into a pre-heated oil bath at 70 oC for 12h. The resultant
mixture was dissolved in dichloromethane (5 mL) and precipitated in hexane (200 mL).
To remove unreactive monomers, the precipitate was further dissolved in
dichloromethane (5 mL) and re-precipitated in ethyl ether (200 mL) to yield purified
random copolymer as a waxy liquid. Yield: 78%. GPC (THF) Mn: 24.7 K. PDI: 1.6. 1H
NMR (400 MHz, CDCl3) δ: 8.40 (a), 7.62 (c, d), 7.05 (b), 4.16-4.02 (i, f), 3.58-3.48 (i),
3.31 (j), 2.97 (e), 2.04-1.65 (h, h’), 1.24-0.72 (g, g’). The molar ratio between the two
blocks was determined by integrating the methoxy proton in the polyethylene glycol
unit and the aromatic proton in the pyridine and found to be 3:7 (PEO:PDSEMA).
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Synthesis of thiol-modified FITC:

A mixture of FITC (10 mg, 0.03 mmol), cystamine dihydrochloride (6 mg, 0.03
mmol) and triethylamine (TECP) (13 mg, 0.13 mmol) was dissolved in DMSO (400 μL)
and stirred for 4 h. To this reaction mixture was added tris(2-carboxyethyl)phosphine
hydrochloride (9 mg, 0.03 mmol) and stirred for 1 h. The resultant mixture was
precipitated in ethyl ether and washed with water. The crude product was used for
nanogel surface modification without further purification.
Synthesis of nanogel containing nile red:

The polymer 1 (10 mg) and Nile red (2 mg) were dissolved in 200 μL of acetone
and measured amount of DTT (4 μmol, 20 mol% against PDS groups) was added. After
stirring for 10 min, 1 mL of deionized water was added and the mixture solution was
stirred overnight at room temperature, open to the atmosphere allowing the organic
solvent to evaporate. Excess insoluble Nile red was removed by filtration and
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pyridothione was removed from the nanogel solution by ultrafiltration (triplicate) using
a membrane with a molecular weight cutoff of 10,000 g mol-1 (Amicon Ultra cell-10K).
Cell culture:
The cell viability of the nanogels was tested against 293T cells. This experiment
has done by Mr. Reuben Chacko. 293T cells were cultured in T75 cell culture flasks
using Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) with
10% fetal bovine serum (FBS) supplement. The cells were seeded at 10,000
cells/well/200 μL in a 96 well plate and allowed to grow for 24 hours under incubation
at 37 oC and 5% CO2. These cells were then treated with nanogels of different
concentrations and were incubated for another 24 hours. Cell viability was measured
using the Alamar Blue assay with each data point measured in triplicate. Fluorescence
measurements were made using the plate reader SpectraMax M5 by setting the
excitation wavelength at 560 nm and monitoring emission at 590 nm on a black well
plate.
Surface modification:
This experiment has done by Mr. Reuben Chacko. FITC or thiol-modified FITC
(1 mg) was dissolved in 100 μL of DMF and then 2 mL of nanogel (1 mg/mL) in water
was added. The mixture solution was stirred overnight at room temperature. Nonconjugated or physically adsorbed dye molecules were removed by ultrafiltration
(thrice) using a membrane with a molecular weight cutoff of 10,000 g/mol. For Tat
peptide modification, 10 μL of nanogel (1mg/mL) which contains 1% DiI molecules
was added to 90 μL of phosphate pH 5 buffer. To this solution, 10 μL of Tat peptide
solution (1 mg/mL) was added. After stirring overnight, 100 μL of this solution was
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added to MCF-7 cells, which were grown in coverslip-bottomed Petri dishes, to make a
total of 2 mL of culture medium. Cells were incubated with surface modified nanogels
and control nanogels for 2 h before confocal imaging.

Figure 2.13. The absorption spectra of nanogel (0.5 mg mL-1) treated with thiolmodified FITC (FITC-SH) and with FITC. To estimate the number of FITC molecules
on the nanogel surface, the absorption of FITC at 492 nm wavelength was compared in
each nanogel treated with FITC-SH and FITC. Based on the calculation of FITC molar
concentration by extinction coefficient and assuming that the nanogel density is around
1.00, the number of FITC molecules on the nanogel surface was determined to be
approximately three thousand molecules per particle.
Laser scanning confocal microscopy:
The laser confocal experiment was performed by Mr. Reuben Chacko. MCF-7
cells were cultured in T75 cell culture flask containing DMEM/F12 with 10% FBS
supplement. 50,000 cells in 2mL of culture medium were seeded in coverslip-bottomed
Petri dishes and allowed to grow for 3 days at 37 oC in a 5% CO2 incubator. These cells
were treated with 100 μL of nanogels and incubated at 37 oC for 2 h before observing
them by confocal microscopy.
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Figure 2.14. Dye release from NG1 (a), NG2 (b), and NG3 (c) (0.05 wt%) in 10 μM
GSH at pH 5.

Figure 2.15: GPC trace of the polymer 1.
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Figure 2.16: 1H-NMR of the polymer 1.
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CHAPTER 3
NONCOVALENT ENCAPSULATION STABILITIES
IN SUPRAMOLECULAR NANOASSEMBLIES
3.1 Introduction
The complications faced in the administration of insoluble and toxic
hydrophobic drugs to target sites have spurred tremendous interest in the field of
delivery vehicle design.(Allen and Culis 2004; Farokhzad and Langer 2009) Of the
many factors considered in such design, the encapsulation stability of the delivery
container is critical.(Savić, Eisenberg et al. 2006; Chen, Kim et al. 2008; Chen, Kim et
al. 2008) Encapsulation of a hydrophobic molecule in aqueous media itself is just an
indicator of the thermodynamic distribution of the molecules between the container and
the bulk solvent. This does not provide indications on the stability of encapsulation in
terms of the dynamics of guest exchange with the bulk media. Understanding the
dynamics of interchange between the bulk solvent and the nanocontainer is crucial, as
this carries clear implications to the potential leakage of encapsulated guest molecules
from the vehicles as they pass through a biological system. Thus, an analysis of this
process is necessary for optimization of the design and construction of drug delivery
carriers.
To probe the stability of encapsulation, we describe here the dynamics of
encapsulated guest interchange in nanocarriers using Fluorescence Resonance Energy
Transfer (FRET) as a tool. We then utilize this method to investigate the stability of
encapsulation in a new class of polymer nanogels and compare it with that observed in
classical amphiphilic nanoassemblies.(Jiwpanich, Ryu et al. 2010)
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A lipophilic FRET pair, 3,3’-dioctadecyloxacarbocyanine (DiO, donor) and
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI, acceptor),
were used for this purpose. These two dye molecules were independently sequestered in
nanocarriers. When the solutions containing the dye molecules were mixed, two
limiting scenarios are possible (Figure 3.1). If the dye molecules are stably encapsulated
and do not exchange the guest molecules with the bulk solvent environment, then the
two dye molecules will continue to be in two separate nanocontainers. If this is the case,
no FRET will be observed since the distance between the two dye molecules is much
higher than their Förster radius. However, if there is a significant exchange of the guest
molecules between the container interior and the bulk solvent when the two solutions
are mixed, it is likely that the dye molecules will equilibrate between the two containers
due to the indistinguishable nature of all nanocarriers in solution. The resulting
equilibration will cause DiI and DiO molecules to occupy the same container, leading to
increased FRET. Thus, tracing the evolution of FRET in such systems provides insight
into the dynamics of guest interchange and potential carrier leakage.

Figure 3.1: Mixed nanogels encapsulating DiI/DiO and their FRET behavior.
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3.2 Results and Discussion
3.2.1 Design and Synthesis
We sought to investigate the versatility of such an approach using cross-linked
polymeric nanogels. The reason for this choice is the assertion that variations in crosslinking densities provide a method for tuning encapsulation stabilities and thus an
opportunity to test our FRET-based strategy. Understandably, this feature also renders
nanogels to be of great interest for controlled release applications in the area of
pharmaceutical and biomedical research.(Byrne, Park et al. 2002; Kopeček 2002;
Hamidi, Azadi et al. 2008; Kabanov and Vinogradov 2009) Generating water-soluble
polymeric nanogels that encapsulate lipophilic molecules can be cumbersome.
However, we have recently introduced a new emulsion-free method for nanogel
preparation in aqueous solution described in Chapter 2 that also provides for facile
hydrophobic guest encapsulation (Figure 1b).(Ryu, Chacko et al. 2010; Ryu, Jiwpanich
et al. 2010)

Scheme 3.1: Synthesis of nanogels containing hydrophobic guest molecules.
To probe the guest exchange dynamics, aqueous solutions of NG1 (6%
crosslinked; ~200 nm in size) containing 1 wt% DiO or 1 wt% DiI were prepared by in
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situ loading (Scheme 3.1). The two solutions containing the separate dyes, referred as
NG1-DiO and NG1-DiI, were then mixed in water. Fluorescence from the DiO
excitation (450 nm) was monitored over time. The evolution of FRET was obtained by
tracing the decrease in the donor (DiO) emission and concurrent increase in acceptor’s
(DiI). The results show that there is a gradual equilibration of the dye molecules over a
48 hour period (Figure 3.2). Interestingly, the thermodynamic distribution of the dye
molecule significantly favors the nanogel interior, as discerned by the overall
concentration of the otherwise insoluble dyes in the aqueous phase.6 Thus, the
continuous interchange of the dyes among the nanocarriers is responsible for observed
enhancement in FRET.

Figure 3.2: (a) Fluorescence emission spectra of mixed NG1 encapsulating DiI/DiO.
(b) Plot of FRET ratio vs time.
The FRET ratio Ia/(Id+Ia), where Ia and Id are the fluorescence intensities of the
acceptor (DiI) and the donor (DiO) respectively, was plotted against time (Figure 3.2).
The slope of the linear fit is related to the dynamics of the guest exchange and we
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define this as the leakage coefficient (Λ), which was found to be about 0.124 h-1 for the
first six hours in NG1 (Figure 3.2).

3.2.2 Tuning Encapsulation Stability
We envisaged that cross-linking density could be used to tune the rate of
exchange/leakage. The preparation method indeed allows for control over the degree of
cross-linking.(Ryu, Chacko et al. 2010; Ryu, Jiwpanich et al. 2010) Accordingly,
nanogels NG1, NG2, and NG3, with cross-linking densities of 6%, 13%, and 25%
respectively, with encapsulated DiI and DiO were prepared. DLS studies reveal that the
structures obtained are all about 200 nm in size (Figure 3.3)

Figure 3.3: DLS traces of nanogels (a) NG1, (b) NG2, (c) NG3.
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Dynamics of guest interchange were monitored and the FRET ratios were
plotted against time. The leakage coefficient (Λ) in supramolecular nanoassemblies was
calculated as shown in Table 3.1. NG2 and NG3 exhibited minimal exchange over 6
hours at an Λ of 0.011 h-1 or below, compared to 0.124 h-1 for NG1 (Figures 3.4). These
results suggest that degree of cross-linking is effective in tuning guest exchange
dynamics. Since the precursor polymer P1 itself is capable of encapsulating DiO and
DiI, we were interested in evaluating the exchange dynamics before and after crosslinking. P1 exhibited a Λ of 0.739 after mixing, indicating rapid guest interchange as
compared to the cross-linked nanogels (Figure 3.4).

Figure 3.4: FRET behavior of mixed nanocontainers encapsulating DiI/DiO: (a) P1, (b)
NG1, (c) NG2, (d) NG3.
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3.2.3 Encapsulation Stability of Supramolecular Nanoassemblies
The key motivation in developing these experiments is to develop a screening
method for probing exchange dynamics, and thus the potential, of drug delivery
vehicles. Therefore, we were interested in investigating the guest exchange
characteristics of other supramolecular assemblies that are known to encapsulate
lipophilic guest molecules (Chart 3.1).

Chart 3.1: Structures of surfactants.
The simplest supramolecular assembly that encapsulates lipophilic guest
molecules involves small molecule surfactant-based micelles (Chart 3.1).(Kabanov,
Nazarova et al. 1995; Savriar, Ghosh et al. 2008; Ryu, Roy et al. 2010) Accordingly, we
encapsulated DiO and DiI in CTAB (cetyl trimethylammonium bromide) and Tween80
micelles and carried out the FRET experiments. Complete equilibration of the dye
molecules was observed instantaneously upon mixing the DiO and DiI based micelles
with the FRET ratios of 0.850 and 0.501 respectively (Figure 3.5).
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Figure 3.5: Fluorescence spectra (λex = 450 nm) of mixed containers encapsulating DiI
and DiO; (a) CTAB, (b) Tween80, (c) Amphiphilic random copolymer, (d) Block
copolymer Pluronic P85.
Since the nanogels are based on polymers, we also investigated other polymerbased nanoassemblies. We measured the guest exchange dynamics of an amphiphilic
random copolymer (structure shown in Chart 3.1).(Ryu, Roy et al. 2010) The guest
exchange rate in these assemblies was found to be 0.788 (Figure 3.5). Similarly, the
encapsulation stability of pluronic block copolymer micellar assemblies,(Kabanov,
Batrakova et al. 2002; Sharma and Bhatia 2004; Batrakova and Kabanov 2008) which
are widely used in biomedical applications, exhibited an Λ of 0.358 (Figure 3.5). This is
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slower than assemblies based on small molecule surfactants and random copolymers,
but faster than the nanogels.
Table 3.1: Leakage coefficient (Λ) in supramolecular nanoassemblies.
Supramolecular nanoassemblies

Leakage coefficient (Λ), h-1

NG1

0.124

NG2

0.011

NG3

0.005

P1

0.739

CTAB

0.850

Tween80

0.501

Random copolymer micelles

0.788

Pluronic® P85

0.358

3.2.4 Triggering Release by External Stimului (GSH)
The results above suggest that the crosslinked polymer nanogels exhibit high
encapsulation stability and the leakage dynamics can be tuned by varying the
crosslinking density. While encapsulation stability is important, a practical delivery
vehicle must also be able to release its contents in response to a biologically-relevant
stimulus. As the nanogels consist of biodegradable disulfide crosslinkers, the release of
encapsulated molecules can be potentially triggered upon exposure to reducing agents.
To test this possibility, we utilized NG2 that exhibited very stable encapsulation.
Glutathione (GSH, 10 mM), a disulfide reducing agent present at higher concentrations
inside cells, was added to the solution containing NG2-DiO and NG2-DiI after 2.5 h.
Significant increase of the FRET ratio was observed at this point (Figure 3a and 3b).
This is presumably caused by dye leakage upon cleavage of the disulfide crosslinkers
due to the presence of GSH, which loosens the gel and reduces encapsulation stability.
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Moreover, significant decreases in the emission intensities of the individual dyes
indicate that the GSH reaction reduces the distribution coefficient of these dyes as well
(Figure 3.11). These results, combined with experiments with NG3, confirm that the
dynamics of guest interchange can be controlled by crosslinking density and that drug
release can be externally triggered (Figure 3.6).

Figure 3.6: Release of dye from mixed nanogels encapsulating DiI/DiO with the
addition of GSH (10 mM) at 2.5 h: (a) NG2, (b) NG3, (c) dynamics of dye exchange in
the presence/absence of GSH (10 mM).
3.3 Summary
In summary, we have developed on a FRET-based method to monitor the guest
exchange dynamics in water-soluble nanoassemblies, which provides insight into the
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leakage characteristics of these nanocontainers. We have thus defined a leakage
coefficient parameter, Λ, from the FRET experiments and analyzed this value for a
variety of nanoassemblies. We find that the guest exchange is slower in crosslinked
polymer nanogels and that this can be conveniently tuned by altering the degree of
crosslinking. We have also investigated the relative guest exchange rates in other
amphiphilic nanoassemblies. We find that while pluronic block copolymers exhibit
higher encapsulation stabilities compared to small molecules and random copolymers,
they do not compare to those offered by crosslinked polymer nanogels. In addition, we
show that the stably encapsulated guests in the nanogels can be released in response to
an external trigger. The dyes employed model the hydrophobic nature of efficacious
drug molecules that commonly face solubility issues during administration. Thus,
understanding the dynamics of encapsulated guest exchange between nanocarriers,
using this method, provides a useful starting point for evaluating viable drug delivery
vehicles. Moreover, the exchange dynamics provide information on the possibility of
utilizing a vehicle to deliver multiple drugs in separate containers with timed release.
These FRET-based studies also highlight the advantages of the newly developed
polymeric nanogels in drug delivery applications.

3.4 Experimental
Materials and Methods
All chemicals and solvents were purchased from commercial sources and were
used as received, unless otherwise mentioned. Pluronic block copolymer P85 (lot no.
WPDF512B) was provided as a gift by the BASF corporation (Mount Olive, NJ).
Polymer P1 was synthesized by RAFT polymerization and then purified by
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precipitation.

S-dodecyl-S’-2-(2,2-dimethylacetic

acid)

trithiocarbonate

and

pyridyldisulfide ethylmethacrylate (PDSEMA) was prepared using a previously
reported procedure.(Lai, Filla et al. 2002; Ghosh, Basu et al. 2006) 1H-NMR spectra
were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton
resonance of the solvent as the internal standard. Chemical shifts are reported in parts
per million (ppm). Molecular weights of the polymers were estimated by gel permeation
chromatography (GPC) using PMMA standard with a refractive index detector.
Dynamic light scattering (DLS) measurements were performed using a Malvern
Nanozetasizer. UV-visible absorption spectra were recorded on a Varian (model EL
01125047) spectrophotometer. The fluorescence spectra were obtained from a JASCO
FP-6500 spectrofluorimeter. Transmission electron microscopy (TEM) images were
taken using a JEOL 100CX at 100 KV.

69

Synthesis of random copolymer (P1):

The polymer (P1) was synthesized by similar method which is published
elsewhere.(Ryu, Jiwpanich et al. 2010) Briefly, a mixture of S-dodecyl-S’-2-(2,2dimethylacetic acid) trithiocarbonate (90 mg, 0.3 mmol), PDSEMA (5 g, 20 mmol),
polyethylene glycol monomethyl ether methacrylate (Mw 450) (4g, 8 mmol) and AIBN
(10 mg, 0.06 mmol) were dissolved in DMF (10 mL) and degassed by performing three
freeze-pump-thaw cycles. The reaction mixture was sealed and then transferred into a
pre-heated oil bath at 70 oC for 12 h. The resultant mixture was dissolved in
dichloromethane (5 mL) and precipitated in hexane (200 mL). To remove unreacted
monomers, the precipitate was further dissolved in dichloromethane (5 mL) and
reprecipitated in ether (200 mL) to yield the random copolymer as a waxy substance.
Yield: 78%. GPC (THF) Mn: 24.7 K. PDI: 1.6. 1H NMR (400 MHz, CDCl3) δ: 8.40 (a),
7.62 (c, d), 7.05 (b), 4.16-4.02 (i, f), 3.58-3.48 (i), 3.31 (j), 2.97 (e), 2.04-1.65 (h, h’),
1.24-0.72 (g, g’). The molar ratio between the two blocks was determined by integrating
the methoxy proton in the polyethylene glycol unit and the aromatic proton in the
pyridine and found to be 3:7 (PEO:PDSEMA). The molar ratio between the two blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit and
the aromatic proton in the pyridine and found to be 3:7 (PEO:PDSEMA).
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Synthesis of nanogels contaning DiI/DiO:
The polymer (2 mg) and DiI or DiO (0.02 mg) were dissolved in 200 μL of
acetone and a measured amount of DTT (0.4 μmol, 0.8 μmol and 2.0 μmol for 10
mol%, 20 mol% and 50 mol% against PDS groups, respectively) was added. The
solution color changed to yellow, indicative of the production of pyridinethione
byproduct of PDS cleavage. After stirring for 10 min, 1 mL of deionized water was
added and the mixed solution was stirred overnight at room temperature, open to the
atmosphere allowing the organic solvent to evaporate. Insoluble DiI/DiO was removed
by filtration and pyridinethione was removed from the nanogel solution by extensive
dialysis using a membrane with a molecular weight cutoff of 10,000 g/mol.

Figure 3.7: Absorption spectra of DiI/DiO in water and in polymer solution.
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DLS measurement:
Dynamic light scattering (DLS) measurements were performed using a Malvern
Nanozetasizer. The light source was solid-stat laser system, operating at 514 nm. The
nanogels in deionized water (1mg/mL) was kept constant at 25 °C throughout the
experiment. Dust was eliminated by filtering the solution through 0.45 µm filter. All
the measurements were done at a correlation time of 30 seconds.

500 nm

Figure 3.8: TEM image of nanogel (NG2).
Micelle encapsulated dye (DiI/DiO) preparation:
A stock solution of dye (3 mg/mL) in acetone was taken (13 µL) in a vial and
the solvent was evaporated by a mild blow of argon gas. To this vial, a 2 mL solution
of the surfactant (concentration well above CMC: CTAB = 2 mM; tween80 =0.03 mM,
polymer micelle = 300 mg/L; Pluronic P85 = 1%wt) was added and the solution was
sonicated for 30 minutes to encapsulate the dye. Insoluble DiI/DiO was removed by
filtering the solution through 0.45 µm filter.
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Nanogel encapsulated dye mixing:
A solution of nanogel containing DiI (100 µL) was mixed with a solution of
nanogel containing DiO (100 µL) in a cuvette, and then milliQ water (800 µL) was
added to adjust the volume.

The fluorescence intensity was recorded at 450 nm

excitation wavelength.
Nanogel encapsulated dye mixing in the presence of GSH:
A solution of nanogel containing DiI (100 µL) was mixed with a solution of
nanogel containing DiO (100 µL), and milliQ water (800 µL) in a cuvette. GSH (3 mg)
was added to the mixed solution at 2.5 hours of mixing. The fluorescence intensity was
recorded at 450 nm excitation wavelength at time interval.
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Figure 3.9: Fluorescence spectra (λex = 450 nm) of mixed nanogels (left), nanogel
containing DiO (middle) and nanogel containing DiI (right); (a) non-crosslinked
polymer (P1), (b) NG1, (c) NG2, and (d) NG3.
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Figure 3.10: Plot of normalized FRET ratio vs time of (a) NG1, (b) NG2, (c) NG3, (d)
comparing the dynamics of leakage/interchange of NG1, NG2, and NG3.

Figure 3.11: Fluorescence spectra (λex = 450 nm) of mixed nanogels (left), nanogel
containing DiO (middle) and nanogel containing DiI (right) with GSH (10 mM) added
at 2.5h; (a) NG2, and (b) NG3.

75

Micelle encapsulated dye mixing:
A solution of micelle containing DiI (0.5 mL) was added to a solution of micelle
containing DiO (0.5 mL). The fluorescence intensity was recorded at 450 nm excitation
wavelength.

Figure 3.12: Fluorescence spectra (λex = 450 nm) of mixed micelle containing DiI and
DiO (left), micelle containg DiO (middle), and micelle containing DiI (right); (a)
CTAB, (b) Tween80, (c) Amphiphilic random copolymers, and (d) Pluronic P85.
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CHAPTER 4
TUNING LOADING CAPACITY AND ENCAPSULATION STABILITY

4.1 Introduction
Nearly one-third of newly discovered drug compounds are highly insoluble in
water.(Lipinski 2000) However, designing water-soluble, nanoscopic drug delivery
vehicles to non-covalently encapsulate such lipophilic molecules and stably transfer
them to target sites still stands as a significant challenge.(Allen and Culis 2004;
Torchilin 2004; Farokhzad and Langer 2009) For drugs administered orally or through
systemic injection, this challenge must be overcome, as low aqueous solubility severely
limits bioavailability and causes non-specific accumulation in healthy tissues that gives
rise to adverse side effects.(Lipinski, Lombardo et al. 2001; Savić, Eisenberg et al.
2006)
Self-assembling polymer micelles are one promising scaffold for lipophilic drug
formulation due to their core-shell structure that allows for the sequestration of
lipophilic molecules into a hydrophobic core that is surrounded by a water-soluble
corona.(Kabanov, Nazarova et al. 1995; Torchilin 2004; Matsumura 2008; Kale,
Klaikherd et al. 2009) However, polymer micelles exhibit inherent stability issues
derived from their concentration-dependent stabilities.(Bae and Yin 2008; Jiwpanich,
Ryu et al. 2010) The requisite concentration for micelle formation (CMC) severely
limits the potential for the use of micelles in vivo, as mass dilution during
biodistribution will cause gradual disintegration of the assemblies into their polymer
constituents.(Chen, Kim et al. 2008; Kim, Shi et al. 2010) Additionally, interactions

79

between micelles and biological components will likely compromise the integrity of the
self-assembling particles, resulting in undesirable release of encapsulated guest
molecules at off-target sites.(Chen, Kim et al. 2008) Furthermore, as discussed in
Chapter 3, the encapsulation stability of hydrophobic compounds sequestered in
micellar assemblies has been shown to be relatively poor.(Jiwpanich, Ryu et al. 2010)
The chemically cross-linked counterparts of polymer micelles, polymer
nanogels, offer the potential to overcome these issues.(Hamidi, Azadi et al. 2008; Oh,
Drumright et al. 2008; Kabanov and Vinogradov 2009; Raemdonck, Demeester et al.
2009; Ryu, Chacko et al. 2010; Vinogradov 2010) We have described in Chapter 2 that
our synthetic method for self-cross-linked polymer nanogels provides an alternative
carrier scaffold that affords the noncovalent trapping of lipophilic molecules in aqueous
media with high encapsulation stability.(Jiwpanich, Ryu et al. 2010; Ryu, Chacko et al.
2010; Ryu, Jiwpanich et al. 2010) In this Chapter, we are particularly interested in
optimizing our cross-linked polymer nanogel system for the solubilization of lipophilic
guests by tuning the hydrophobicity of the nanogel network. We describe the effect of
varying the lipophilic content of the polymer nanogels on observed loading capacities
and encapsulation stabilities. We hypothesized that increasing hydrophobicity in
nanogel interior would enhance the loading capacity and efficiency for lipophilic
molecules.
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Figure 4.1: Cartoon representation of self-cross-linked nanogels with lipophilic guest
encapsulation.
The nanogel delivery system we have discussed in Chapters 2 and 3 is based on
random copolymers that contain oligoethyleneglycol (OEG) and pyridyldisulfide (PDS)
units. In order to vary the hydrophobicity inside the cores of the self-cross-linked
nanogel networks, the polymer precursor will be modified with lipophilic alkyl groups
as additional side chain functionalities (Figure 4.1). The consequences of the induced
changes in the hydrophobic-lipophilic balance (HLB) of the polymer aggregates, and
thus the obtained nanogel carriers, to loading capacity and encapsulation stability is
investigated using the FRET based method described in Chapter 3. We expected that: (i)
the use of a random copolymer containing hydrophilic and lipophilic functionalities as a
nanogel precursor will allow for aggregate formation prior to cross-linking; (ii)
increasing the contribution of the hydrophobic alkyl component will provide enhanced
lipophilic guest encapsulation capacity; (iii) the encapsulation stability of lipophilic
guest molecules trapped inside the cross-linked nanogel networks can be tuned by
varying the hydrophobicity of the precursor polymers.
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4.2 Results and Discussion
4.2.1 Design and Synthesis
In order to test the effect of varying hydrophobicity on the various parameters
of lipophilic encapsulation in our self-cross-linked nanogel system, amphiphilic random
copolymer precursors with varying hydrophobic content were synthesized. Drawing
from our previously explored PEG-PDS copolymer, which used the contained PDS side
chains as a handle for the cross-linking of the nanogel structure, polymer precursors for
these studies were designed to contain a constant amount of the PDS functionality that
was determined sufficient to achieve to self-cross-linking reaction. The OEG units were
again included as water soluble, biocompatible functionalities and constituted the major
hydrophilic content of the precursor polymers. To achieve precursor polymers with
variable hydrophobic content, lipophilic alkyl chain functionalities were added to the
OEG-PDS composition. The relative hydrophobicities of the precursor polymers were
varied in two different manners: (i) by varying the length of the alkyl chain contained in
the incorporated comonomer and (ii) by altering the ratio of comonomers containing a
constant length alkyl chain to those containing the hydrophilic OEG group. The
synthesized polymer structures are shown in Chart 4.1. Both sets of polymer nanogel
precursors were prepared by reversible addition-fragmentation chain transfer (RAFT)
polymerization.
For the first series, four polymers (P1-P4) were prepared to contain 50% of the
OEG methacrylate, 20% of the PDS-derived methacrylate, and 30% of alkyl
methacrylate. Within this polymer series, the alkyl chain (denoted by R in Chart 4.1a)
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length is varied to generate polymers P1 (R = butyl), P2 (R = hexyl), P3 (R = octyl),
and P4 (R = decyl).

Chart 4.1: Structures of polymer precursors.
For the second series, two additional polymers (P5-P6) were prepared with
varying percentages of the incorporated alkyl-containing comonomer. For this purpose,
we chose the decylmethacrylate comonomer as the lipophilic side chain and varied the
ratio of this hydrophobic commoner to OEG while keeping the PDS monomer at a
constant 20 mol%. Combining polymer P4 from the first series with polymers P5 and
P6, a series was generated in which the ratio of OEG methacrylate to decylmethacrylate
to PDS methacrylate was made to equal 50%:30%:20%, 40%:40%:20% and
30%:50%:20%, respectively.
Since polymers P1-P6 contain both hydrophobic alkyl groups and hydrophilic
OEG side chain units, these polymers were observed to exhibit core-shell like
structures, similar to those observed with micellar assemblies, when they were allowed
to self-assemble in aqueous solution. Such aggregation of the amphiphilic random
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copolymers generated assemblies with lipophilic cores that could accommodate the
sequestration of lipophilic guest molecules in water. Using the procedure described in
Chapter 3, two FRET pair dye molecules (DiI and DiO) were independently loaded into
the cores of these polymer aggregates. Subsequent addition of the reducing agent, DTT
(0.5 equivalents with respect to PDS groups in the precursor polymer), activated the
intra/interchain disulfide bond formation that has been shown to generate the crosslinked polymer nanogel structure (Scheme 4.1). Polymer nanogels, NG1-NG6, were
prepared from the polymer precursors, P1-P6, respectively. Performing this preparation
in the presence of either DiI or DiO allowed these lipophilic dyes to efficiently
accumulate within the hydrophobic cores of the formed polymer aggregates, achieving
noncovalent encapsulation within the obtained water soluble nanogel carriers after
crosslinking.

Scheme 4.1: Synthesis of the self-cross-linked polymer nanogels from precursor
polymers containing OEG, PDS and hydrophobic alkyl groups.
We investigated the aggregation sizes of polymers P1-P6 in water prior to crosslinking by dynamic light scattering (DLS), as it was hypothesized that the sizes of these
assemblies would dictate the sizes of the obtained nanogels (NG1-NG6). Solutions of
polymers P1-P6 (10 mg.mL-1) in water displayed assembly sizes with diameters
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centered at around 10 nm by volume based DLS measurement (Figure 4.2a). The
nanogels formed from these polymer precursors exhibited similar sizes to those
observed for their corresponding aggregates with the exception of the butylmethacrylate
containing NG1, which showed a larger size centered at around 200 nm diameter
(Figure 4.2b). It is hypothesized that this discrepancy may be due to a lack of stable
polymer aggregation exhibited by P1. Polymer P1 contains 30% of the
butylmethacrylate side chain, which is the shortest lipophilic side chain used in the
present work. Considering the contribution to the overall aggregate HLB from the 50%
of hydrophilic OEG segments, it is likely that this butyl chain does not sufficiently
stabilize the observed 10 nm polymer aggregate. Such instability increases the
probability of interaggregate cross-linking occurring during the DTT initiated reaction,
resulting in a larger polymer nanogel than those formed from the more stabilized
aggregates of polymers P2-P6.

Figure 4.2: Size distributions in water by volume based DLS for a) polymer aggregates
of P1-P6 (10 mg.mL-1) and b) self-cross-linked polymer nanogels, NG1-NG6.
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4.2.2 Hydrophobic Effect on Loading Capacity
Dominated by the hydrophobic effect and polymer-drug miscibility, loading in
polymer micelles has been shown to be highly dependent on HLB, with enhanced
loading observed when the length or density of the hydrophobic block is increased.(Li,
Danquah et al. 2010) Considering this fact, we were interested in tuning the loading
capacity for lipophilic guest molecules in our polymer nanogel system by varying the
hydrophobic content of our nanogel constructs. To investigate this possibility, the
polymer series P1-P6 described above was synthesized. Nanogels, NG1-NG6, were
prepared from these polymers using the DTT initiated crosslinking reaction in the
presence of either DiI or DiO to afford noncovalent encapsulation of one of the FRET
pair dyes within the nanogel interior. Polymer nanogels, NG1-NG4, were separately
loaded in situ with DiI and DiO using 2 wt% of the lipophilic dyes. After filtering off
unencapsulated dye molecules and removing the pyridothione crosslinking reaction
byproduct by dialysis, the extent of guest encapsulation in solution of mixed DiI and
DiO samples was measured by UV-Vis spectroscopy. The absorption spectra (solid
lines) of these dye loaded nanogels, shown in Figure 4.3, reveal a clear trend of
increasing dye encapsulation as the length of the lipophilic alkyl chain is increased from
butyl (NG1) to decyl (NG4).

This is attributed to the increasingly hydrophobic

environment created by these alkyl chains within the nanogel cores that can favorably
accommodate liphophilic guests.
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Figure 4.3: Hydrophobic effect of cross-linked polymer nanogels on loading capacity:
2 wt% of dye feeding solution (solid line); 10 wt% of dye feeding (broken line).
While this trend is rather clear, two questions may be raised from these spectra.
The first is the clear difference in spectrum shape of the dye pair encapsulated in NG1
from that observed in with all other nanogel solutions. While the exact cause of this
discrepancy is unclear, we expect that it is an effect of a very different core environment
in this nanogel structure; a combination of the loose packing of the short butyl chain
and the larger size (~200 nm) of the nanogels makes the interior of NG1 relatively
hydrophilic as compared to the rest of the series, a feature which likely alters the
absorbance characteristics of the encapsulated dye molecules.
Second is the similarity in absorbance of the dyes encapsulated within the decyl
containing NG4 and those encapsulated within the octyl containing NG3. This suggests
that these two polymers display similar loading with an equal feed amount of dye.
However, we hypothesize that this 2 wt% dye feeding, while above the 100% loading
efficiency thresholds of NG1-NG3, was at a point where the loading efficiency of NG4
was near 100%. In this case, the apparent loading capacity of NG4 may have been
limited by the feeding dye concentration. We tested this hypothesis by increasing the
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feed concentration of dye from 2 wt% to 10 wt%. The enhanced dye encapsulation
observed with NG4 (broken red line) confirms that 2 wt% is well below the dye amount
that this nanogel can absorb with nearly perfect loading efficiency and that more dye
can be encapsulated (with less than 100% efficiency) when higher dye concentration is
used during preparation.
We were also interested in investigating the hydrophobic effect on loading
capacity with the NG4-NG6 series, in which the nanogel hydrophobicity was varied by
altering the ratio of decyl chains to OEG units. Dye loaded NG4-NG6 were prepared by
in situ loading of 10 wt% DiI or DiO during the DTT crosslinking reaction. The
obtained nanogels, all of constant crosslinking degree, contain OEG:decyl ratios of
50:30 (NG4), 40:40 (NG5) and 30:50 (NG6). Analysis of the spectra shown in Figure
4.3 (broken lines), reveals increasing dye encapsulation as the relative percentage of the
decylmathecrylate monomer in the precursor polymer is increased. Similar to the effect
of increasing the length of the alkyl chain, increasing the amount of decyl chains within
the polymer enhances the hydrophobicity of the interior of the formed aggregates and
creates an increasingly preferential nanogel core for the encapsulation of lipophilic
guest molecules. Interestingly, NG4 in this series exhibited much higher encapsulation
than its counterpart in the first series, suggesting that 2 wt% was well below its maximal
loading capacity.

4.2.3 Hydrophobic Effect on Encapsulation Stability
Having demonstrated that the loading capacity for lipophilic guest molecules
can be tuned in our nanogel system by introducing hydrophobic variations into the
precursor polymers, we were next interested in investigating the consequences that such
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variations would have on the encapsulation stabilities in the prepared nanogel carriers.
For this purpose, we have used our FRET based method described in Chapter 3 to
quantitatively compare the encapsulation stabilities exhibited by dye loaded nanogels,
NG1-NG6. The same nanogel samples used for the analysis of loading capacities were
used in these experiments. Nanogel samples containing encapsulated DiI were mixed
with those containing DiO and the evolution of FRET between the dye pair, indicated
by concomitant decrease in donor (DiO) intensity at 505 nm and increase in acceptor
(DiI) intensity at 568 nm, was followed over a 24 hour period.
It was hypothesized that the by increasing the hydrophobicity of the nanogel
core through variations to the precursor polymer we would be able to enhance not only
the loading capacities of the obtained carriers, but also the encapsulation stability of
lipophilic guests sequestered within the nanoassemblies. This was based on the thought
that an increasingly hydrophobic core would provide a better environment for the
solubilization of lipophilic guests, enhancing the ability of the nanogel to hold on to its
guest molecules and limiting exchange with the aqueous bulk environment.

89

Figure 4.4: Fluorescence spectra (λex = 450 nm) of mixed nanogels containing DiI and
DiO prepared with 2 wt% dye loading: a) NG1, b) NG2, c) NG3, and d) NG4.
This was first tested with the NG1-NG4 series, which was prepared with 2 wt%
feeding of the dyes. The time-dependent FRET evolution for these nanogels is plotted in
Figure 4.4. Interestingly, the recorded FRET development behaviors did not support our
originally proposed hypothesis. In fact, analysis of NG1-NG3 indicates the exact
opposite trend, with a more rapid rate of FRET evolution being observed as the length
of the incorporated alkyl chain increases from butyl to hexyl to octyl (Figure 4.4 a, b, c).
However, it is also noted from these plots that the FRET evolution for the decyl
containing NG4 (Figure 4.4d) deviates from this trend. As this NG4 sample was
previously shown to be well below its maximal loading capacity, an alternate
hypothesis, taking into account the observed effects on both encapsulation capacity and
stability, was formulated to explain this behavior.
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It was demonstrated in the previous section that the capacity for lipophilic
encapsulation is enhanced as the length of the alkyl chain within the polymer nanogel is
increased. The amphiphilic nature of the precursor polymer is thought to induce
formation of a micelle-type aggregate, in which the majority of hydrophobic content is
buried within the core of the self-assembling construct. If this is the case, a likely
feature of lipophilic encapsulation in these systems is that initially sequestered guest
molecules accumulate deep within the core and gradually move out towards the
assembly periphery as core volume is filled. The extent of such peripheral loading in
this system will necessarily be dependent on the nature (length and density) of the
hydrophobic units dispersed throughout the random compolymer network and the
amount of dye used during the nanogel preparation. Thus, as the length of the alkyl
chain is increased from NG1 to NG4, the observed increase in loading capacity could
be due, in part, to an enhanced ability to load lipophilic dye molecules closer to the
nanogel surface. However, it is also a reasonable assumption that these peripherally
loaded dye molecules will be those that are least stably encapsulated and most easily
exchange with the bulk environment. This would explain why enhanced loading
observed going from NG1 to NG3 translates to faster FRET evolution and less stable
encapsulation. It would also rectify the apparent aberration with NG4, as the majority of
the 2 wt% dye used is likely stably encapsulated within the core of this nanogel, which
is below its maximal capacity, and does not leak out into the aqueous exterior.
To test this hypothesis, we investigated the encapsulation stability of the NG4NG6 series prepared using 10 wt% of DiI and DiO. According to the new hypothesis,
we expected to observe faster rates of FRET exchange with greater dye loading caused
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by an increasing relative amount of the decyl unit in nanogels NG4 to NG6. We were
gratified to observe that this was indeed the case. NG4, containing a 50:30 ratio of OEG
to decyl chain, exhibited the lowest dye encapsulation with the 10 wt% feeding but also
displayed gradually increasing FRET over the tested 24 hour period (Figure 4.5a). NG5,
with a ratio of 40:40, encapsulated an intermediate amount of dye and exhibitied much
faster FRET development (Figure 4.5b). Finally, NG6, containing a 30:50 ratio,
encapsulated the highest amount of dye and displayed a very rapid burst of FRET
evolution, with the majority of exchange occurring within the first three hours of the
experiment (Figure 4.5c).

Figure 4.5: Fluorescence spectra (λex = 450 nm) of mixed nanogels encapsulated DiI
and DiO prepared with 10% dye loading; a) NG4, b) NG5, and c) NG6.
The apparent inverse relationship between loading amount and encapsulation
stability is clearly seen in the plots of FRET ratio vs. time for the NG1-NG4 and NG4NG6 series (Figure 4.6). The FRET ratio Ia/(Id+Ia), where Ia and Id are the fluorescence
intensities of the acceptor (DiI) and the donor (DiO), respectively, is a used as a
quantitative comparison of the extents of dye leakage observed for each nanogel
sample. As described in Chapter 3, the development of FRET between the
independently sequestered DiO and DiI molecules is dependent on leakage from the
nanocarrier in which they were originally encapsulated and subsequent uptake by a
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different container in the aqueous solution. This will cause increasing accumulation of
both DiO and DiI within their Förster radius in the cores of the same nanocarrier,
leading to increased energy transfer between the two dyes. While the data reported in
this section supports the hypothesis of loading dependent encapsulation stability, there
exists an alternate explanation that must be addressed.

Figure 4.6: Plot of FRET ratio vs time; a) chain length variation prepared from 2 wt%
dye stock solution, b) alkyl group percentage variation prepared from 10 wt% (solid
link) and 2 wt% (dot line) of dye stock solution.
The observed development of FRET using this method is dependent on the
relative rates of two distinct events. The first is the leakage of dye molecules from the
interior of the originally encapsulating nanogel into the aqueous exterior. The second is
the re-encapsulation of leaked dye molecules into the interior of some nanogel present
in solution. While increasing the hydrophobicity of the nanogel material has been
shown to limit the first process, it is also possible that it has an effect on the second
process. Specifically, increasing hydrophobicity of the nanogel could enhance its ability
to sequester leaked dye molecules from the aqueous environment. The fact that no
significant changes in either dye’s absorbance were observed with any sample over the
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lifetime of the experiment (Figure 4.7) suggests that this is not the case. However, it
could be that the increasingly hydrophobic nanogels tend to re-encapsulate within their
core, causing close proximity of the sequestered dyes, whereas lower hydrophobicity
only affords uptake from the exterior along the surface of the nanogel.

Figure 4.7: Absorbance of mixed nanogels encapsulated DiI and DiO prepared with
10% dye loading; a) NG4, b) NG5, and c) NG6.
4.2.4 Correlating Loading Capacity and Encapsulation Stability
To distinguish between these two possibilities, an additional experiment using
nanogels NG4-NG6, which were loaded with a normalized amount of DiI and DiO well
below the maximal loading capacities of these decyl containing gels, was performed.
The nanogel samples were prepared using 1 wt% of the two dyes. UV-vis absorbance
spectra taken of the purified samples (Figure 4.8) reveal an equal level of encapsulation
in all three nanogels, which was calculated to correspond to nearly 100% encapsulation
efficiency.
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Figure 4.8: Dye encapsulation in samples of mixed NG4-NG6 prepared using 1wt% of
both DiI and DiO.
The DiI and DiO containing samples were mixed and the FRET development for
these normalized loading nanogels was monitored. This experiment was performed to
test the hypothesis of loading dependent encapsulation stability. With all tested samples
being normalized to a dye amount well below their maximal encapsulation capacity, we
expected the true effect of increasing nanogel hydrophobicity on encapsulation stability
to determine the rate of guest exchange. Thus, if our hypothesis were true, we expected
that the enhanced lipophilicity of the nanogel core provided by an increasing number of
decyl chains in the precursor polymer would allow for more stable guest encapsulation,
preventing exchange with the bulk exterior and limiting the development of FRET. If
the alternate possibility were true, any leakage from the more hydrophobic samples
would lead to an increase in FRET due to the enhaced abilities of these nanogels to
uptake leaked guests from the aqueous exterior.
The plots of FRET development observed for NG4-NG6 (Figure 4.9) support
the first case, revealing decreased FRET development over time as the percentage of
decyl group within the nanogel is increased. NG4, containing 30% of the decyl unit,
displays a gradual, sustained increase in FRET over the tested 72 hour period (Figure
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4.9a). NG5, containing 40% of the decyl chain, displays enhanced encapsulation
stability, only beginning to show FRET development at 24 hours after mixing (Figure
4.9b). Finally, the 50% decyl containing NG6 displays superior encapsulation stability,
with no observed FRET development over the tested 72 hour period (Figure 4.9c).
These results clearly demonstrate the effect of increasing hydrophobicity on the
encapsulation stability exhibited by our nanogel carriers. Specifically, at less than
maximal loading capacity, introducing hydrophobic groups into the nanogel scaffold
can be used to greatly enhance the encapsulation stabilities of these nanoscopic carriers.

Figure 4.9: Fluorescence spectra (λex = 450 nm) of mixed nanogels encapsulated DiI
and DiO prepared with 1 wt% dye loading; a) NG4, b) NG5, and c) NG6.
4.3 Summary
In this Chapter, we have examined the effect of hydrophobic composition on
the container properties of our nanogel system, specifically in reagrds to loading
capacity and encapsulation stability. Modifying the previously explored PEG-PDS
copolymer to contain hydrophobic alkyl groups, two series of random copolymers were
generated. The hydrophobicity of the first series, NG1-NG4, was varied by altering the
length of the alkyl chain incorporated into the precursor polymers from butyl to decyl
with two carbon increments. The hydrophobicity of the second series, NG4-NG6, was
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varied by targeting OEG:decyl ratios within the polymers of 50:30, 40:40 and 30:50
while keeping the PDS unit at a constant 20%.
By carrying out the DTT initiated crosslinking reaction in the presence of the
lipophilic dyes, DiI or DiO, we were able to achieve in situ loading within the interiors
of the formed nanogels. The loading capacity and efficiency was shown to be directly
dependent on the hydrophobicity of the nanogel composition. Specifically, the loading
capacities of these nanogel carriers can be enhanced by increasing the hydrophobic
content of the structures, either through size or density of the incorporated lipophilic
functionalities.
Nonetheless, encapsulation stability at maximal loading was observed to
decrease as the hydrophobicity within the nanogels increased. Enhanced loading in a
more hydrophobic nanogel is due, in part, to increased peripheral loading of the dye
molecules. As a result, highly hydrophobic nanogels that were loaded with dye well
below their maximal loading capacities were able to hold on to their encapsulated
guests molecules with enhanced stabilities.
These results provide crucial insight into the optimization of loading paramters
for this nanogel system and other nanoscopic delivery vehicles. Notably, this work
suggests that loading capacity and encapsulation stability cannot be maximized
simultaneously, with an optimal balance occurring well below the maximal loading
capacity of a given nanocarrier. As one of the major focuses in the future development
of nanoparticle enabled drug delivery systems is the improvement of loading capacity,
this trade off must be taken as a crucial consideration. It should be noted that the
nanogels employed in this study were designed to explore the structure-property
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relationship between scaffold hydrophobicity and container ability. Emphatically, these
nanogels were not optimized for the loading capacities or efficiencies required for any
biologically relevant applications. Nonetheless, we believe that the observed loading
depedent encapsulation stability behavior is a basic property of the nanoscopic vehicle
and its implications will translate to other carrier scaffolds. The reported FRET based
system is a rather robust method, capable of detecting guest molecule leakage in cases
where UV-vis, simple fluorescence, and traditional FRET based experiments yield a
false impression of in vitro encapsulation stability. This method may be widely
employed to determine an optimal balance of stable lipophilic guest molecule loading
for nanoscopic drug delivery vehicles.

4.4 Experimental
Materials and Methods
All chemicals and solvents were purchased from commercial sources and were
used as received, unless otherwise mentioned. Polymers P1-P6 were synthesized by
RAFT polymerization and purified by precipitation. S-dodecyl-S’-2-(2,2-dimethylacetic
acid) trithiocarbonate and pyridyldisulfide ethylmethacrylate (PDSEMA) were prepared
using previously reported procedures.(Lai, Filla et al. 2002; Ghosh, Basu et al. 2006)
1

H-NMR spectra were recorded on a 400 MHz Bruker NMR spectrometer using the

residual proton resonance of the solvent as the internal standard. Chemical shifts are
reported in parts per million (ppm). Molecular weights of the polymers were estimated
by gel permeation chromatography (GPC) using a PMMA standard with a refractive
index detector. Dynamic light scattering (DLS) measurements were performed using a
Malvern Nanozetasizer. UV-visible absorption spectra were recorded on a Varian
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(model EL 01125047) spectrophotometer.

The fluorescence spectra were obtained

using a combination of PTI and JASCO FP-6500 spectrofluorimeters.
General procedure for Syntheses of random copolymers:
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Briefly, a mixture of S-dodecyl-S’-2-(2,2-dimethylacetic acid) trithiocarbonate (CTA),
PDSEMA, poly(ethylene glycol) methyl ether methacrylate (PEGMA, Mw 475), the
alkyl chain derived methacrylate monomer and AIBN were dissolved in THF and
degassed by performing three freeze-pump-thaw cycles. The reaction mixture was
sealed and transferred into a pre-heated oil bath at 70 oC for 12 h. The resultant mixture
was dissolved in dichloromethane (0.1 mL) and precipitated in hexane (5 mL). To
remove unreacted monomers, the precipitate was further dissolved in dichloromethane
(0.1 mL) and reprecipitated in ether (5 mL) to yield the random copolymer as a pale
yellow, waxy substance.
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Synthesis of P1:
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According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (930 mg, 1.9
mmol), butylmethacrylate (170 mg, 1.2 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.6 mL). GPC (THF) Mn: 55K. PDI: 2.2. 1H NMR (400 MHz,
CDCl3) δ 8.44 (a), 7.66 (b), 7.10 (c), 4.20 (d), 4.05 (e), 3.89 (f), 3.60 (g), 3.34 (h), 3.00
(i), 2.04-1.80 (j), 1.80-1.22 (k), 1.01-0.78 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 5:3:2 (PEO:ButylMA:PDSEMA).
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Synthesis of P2:
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According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (930 mg, 1.9
mmol), hexylmethacrylate (200 mg, 1.2 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.7 mL). GPC (THF) Mn: 38K. PDI: 1.5. 1H NMR (400 MHz,
CDCl3) δ 8.48 (a), 7.70 (b), 7.13 (c), 4.22 (d), 4.08 (e), 3.91 (f), 3.64 (g), 3.37 (h), 3.04
(i), 2.10-1.60 (j), 1.40-1.20 (k), 1.10-0.78 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 5:3:2 (PEO:HexylMA:PDSEMA).
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Synthesis of P3:
m

O

l

j

9

O

0.5n
O

e

f

l

j

0.3n
O

O

d

j

0.2n
O

g

i

O
h

S
b

k
b

S
N

c

a

l

According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (930 mg, 1.9
mmol), octylmethacrylate (230 mg, 1.2 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.7 mL). GPC (THF) Mn: 41K. PDI: 1.4. 1H NMR (400 MHz,
CDCl3) δ 8.48 (a), 7.70 (b), 7.13 (c), 4.22 (d), 4.08 (e), 3.91 (f), 3.64 (g), 3.37 (h), 3.04
(i), 2.10-1.60 (j), 1.40-1.20 (k), 1.20-0.78 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 5:3:2 (PEO:OctylMA:PDSEMA).
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Synthesis of P4:
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According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (930 mg, 1.9
mmol), decylmethacrylate (270 mg, 1.2 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.8 mL). GPC (THF) Mn: 49K. PDI: 2.1. 1H NMR (400 MHz,
CDCl3) δ 8.45 (a), 7.66 (b), 7.10 (c), 4.19 (d), 4.05 (e), 3.88 (f), 3.61 (g), 3.35 (h), 3.04
(i), 2.10-1.60 (j), 1.50-1.20 (k), 1.10-0.70 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 5:3:2 (PEO:DecylMA:PDSEMA).
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Synthesis of P5:
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According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (740 mg, 1.6
mmol), declmethacrylate (350 mg, 1.6 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.6 mL). GPC (THF) Mn: 42K. PDI: 2.0. 1H NMR (400 MHz,
CDCl3)δ 8.43 (a), 7.65 (b), 7.09 (c), 4.18 (d), 4.04 (e), 3.72 (f), 3.70 (g), 3.33 (h), 3.04
(i), 2.10-1.55 (j,k), 1.48-1.20 (k), 1.10-0.70 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 4:4:2 (PEO:DecylMA:PDSEMA).
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Synthesis of P6:
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According to general procedure for synthesis of random copolymers, a mixture
of CTA (14.0 mg, 0.04 mmol), PDSEMA (200 mg, 0.78 mmol), PEGMA (560 mg, 1.2
mmol), decylmethacrylate (440 mg, 2.0 mmol) and AIBN (1.3 mg, 7.8 µmol) were
polymerized in THF (2.4 mL). GPC (THF) Mn: 52K. PDI: 2.2. 1H NMR (400 MHz,
CDCl3)δ 8.45 (a), 7.65 (b), 7.09 (c), 4.19 (d), 4.05 (e), 3.88 (f), 3.61 (g), 3.34 (h), 3.00
(i), 2.10-1.50 (j,k), 1.40-1.20 (k), 1.10-0.80 (l). The molar ratio between the three blocks
was determined by integrating the methoxy proton in the polyethylene glycol unit,
methoxy proton in alkyl derived methacrylate, and the aromatic proton in the pyridine
and found to be 3:5:2 (PEO:DecylMA:PDSEMA).
Synthesis of nanogels contaning DiI/DiO:
Polymers P1-P6 (2 mg) and DiI or DiO (0.02 mg for 1 wt%, 0.04 mg for 2 wt%
and 0.2 mg for 10 wt%) were dissolved in 200 μL of acetone and a calculated amount of
DTT was added. The solution color changed to yellow, indicative of the production of
pyridinethione byproduct of PDS cleavage. After stirring for 10 min, 1 mL of deionized
water was added and the mixed solution was stirred overnight at room temperature,
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open to the atmosphere to allow the organic solvent to evaporate. Insoluble DiI/DiO
was removed by filtration and pyridinethione was removed from the nanogel solution
by extensive dialysis using a membrane with a molecular weight cutoff of 10,000
g/mol.
DLS measurement:
Dynamic light scattering experiments were performed by using a Malvern
Nanozetasizer. The light source was solid-state laser system, operating at 514 nm. The
nanogels in deionized water (1mg/mL) were kept constant at 25 °C throughout the
experiment. Dust was eliminated by filtering the solution through 0.45 µm filter. All
the measurements were done at a correlation time of 30 seconds.
Nanogel encapsulated dye mixing:
A solution of nanogel containing DiI (100 µL) was mixed with a solution of
nanogel containing DiO (100 µL), and milliQ water (800 µL) in a cuvette.
fluorescence intensity was recorded at 450 nm excitation wavelength.
Table 4.1: Leakage coefficient (Λ) in supramolecular nanoassemblies.
Nanogels-loading (wt%)

Leakage coefficient (Λ), h-1

NG1-2 wt%

0.035

NG2-2 wt%

0.053

NG3-2 wt%

0.063

NG4-1 wt%

0.024

NG4-2 wt%

0.021

NG4-10 wt%

0.044

NG5-1 wt%

0.002

NG5-10 wt%

0.091

NG6-1 wt%

-0.001

NG6-10 wt%

0.107
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS

5.1 Introduction
This dissertation describes a new class of self-cross-linked polymer nanogels
which provide a versatile platform for the development of novel nanoscopic drug
delivery systems. The nanogels were synthesized by intra-/intermolecular disulfide
cross-linking reaction and provide non-colvalent hydrophobic encapsulation capabilities
with high encapsulation stability and controlled release of the payload. These crosslinked polymer nanogels are considered as potential carriers for use in drug delivery
systems since thier cross-linked nature holds the polymer network together creating
stable nanocontainers. In addition, the cross-linked polymer nanogels have no
concentration dependent (CMC) or stability issues commonly observed with classical
polymeric nanoassemble systems. It is important to note that polymer nanogels are of
interest in the field of drug delivery and have been reported in the literature recently;
however, the classical emulsion/inverse emulsion preparation method still faces certain
complications described in Chapter 1.(Oh, Siegwart et al. 2007; Oh, Tang et al. 2007;
Hamidi, Azadi et al. 2008; Oh, Drumright et al. 2008; Kabanov and Vinogradov 2009;
Raemdonck, Demeester et al. 2009; Vinogradov 2010)
In this dissertation, we mainly focus on the development of a synthetic method
for cross-linked polymer nanogels for drug delivery systems and utilizing this system
for lipophilic drug delivery applications. In Chapter 2, we highlight our methodology
development using intra-/intermolecular disulfide cross-linking with PDS containing
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polymers. Through the use of a simple inter-/intramolecular self-cross-linking reaction,
we have elaborated an emulsion-free method for the synthesis of well-defined,
biocompatible nanogels.(Ryu, Chacko et al. 2010; Ryu, Jiwpanich et al. 2010) This
cross-linking method is based on the presence of pyridyl disulfide (PDS) units in the
precursor polymer chain. By addition of deficient amount of the reducing agent DTT,
we are able to achieve nanogel formation through the formation of cross-linking
disulfide bonds with hydrophobic encapsulation capabilities. The surface of self-crosslinked nanogels can be tailored with targeting ligands containing thiol through the
remaining PDS groups.
As we mentioned above, the cross-linked nature of nanogels is of great interest
for the potential drug delivery systems since it provides not only stable nanocarriers but
also tunable encapsulation stability. In Chapter 3, we detailed a FRET based method as
a tool to probe the encapsulation stability of non-covalently encapsulated lipophilic
molecules in self-assembled nanocontainers.(Jiwpanich, Ryu et al. 2010) A FRET pair
(DiI and DiO) was encapsulated into separate nanocontainers independently, and were
then mixed. The evolution of FRET, readout for guest exchange dynamics, was
monitored in the mixed solution. This simple method provides a useful starting point for
evaluating viable drug delivery vehicles. Based on FRET-based studies, we have shown
that our self-cross-linked polymer nanogels show high encapusltion stability and the
release profile of stably encapsulated guest can be tuned by the cross-linking density.
In order to maximize loading capacity of lipophilic guest molecules in selfcross-linked polymer nanogels, in Chapter 4, we describe the use of a hydrophobic
polymer to provide a hydrophobic pocket inside the nanogel network. The increased
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hydrophobicity of the polymer backbone increases the lipophilic loading capabilities.
Nonetheless, the maximum loading of lipophilic molecules into self-cross-linked
polymer nanogels may cause leakage due to the surface bound lipophilic guest
molecules. We highlight these issues so that the drug molecule leakage will be
considered as a potential problem and due attention will be paid while designing novel
nanoscopic carriers for drug delivery.
The newly developed self-cross-linked polymer nanogels described in this
dissertation is based on disulfide self-cross-linking reaction and the initial findings of
the cross-linked polymeric nanogels described here show great promise as therapeutic
carrier scaffolds. In the following sections, we discuss the ongoing work in our research
group.

5.2 Future Directions
5.2.1 Controlled Release inside Cells
The two key findings of the self-cross-linked polymer nanogels i.e., the stable
drug encapsulation, and prevention of premature drug leakage render them great
potential to carry lipophilic drugs into cancer cells. We are interested in testing the
release of loaded cargo in the cross-linked polymer nanogels inside the cells having
high glutathione (GSH) concentration, and also in delivering lipophilic cancer drugs
into tumor cells. The preliminary results demonstrate that our cross-linked nanogels are
able to transfer the loaded cargo inside the cells as shown in Figure 5.1. In this
experiment, we co-encapsulate a FRET pair (DiI and DiO) in a nanogel and monitor the
dye release inside MCF-7 cells which is known to have high levels of GSH. When the
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FRET pair is stably encapsulated in the network interior, FRET (red color) will be
observed, while the disappearance of FRET (more yellow) is an indication of dye
release. As shown in Figure 5.1, both nanogels having 6% and 27% cross-linking
display the ability to enter into cells and that the release kinetics are controlled by the
cross-linking density. The 6% cross-linked nanogels release its cargo faster than 27%
cross-linked nanogels.

Figure 5.1: Confocal microscopy images of nanogels containing DiI and DiO at 4h and
24h incubation times: a) 6% cross-linked nanogels; b) 27% cross-linked nanogels.
Overall, the polymer nanogels developed by us hold great potential for drug
delivery especially for chemotherapeutics. The in vivo delivery of cancer drugs such as
doxorubicin to the breast cancer animal models is under investigation.
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5.2.2 Cross-linked Nanogels with Cross-linker Modification
In this dissertation, we elaborate on the development of self-cross-linked
polymer nanogels using disulfide self-cross-linking reaction by holding the amphiphilic
polymer aggregation to create stable nanoparticles with hydrophobic encapsulation
capabilities. Although, the nanogels based on disulfide cross-linker can be cleaved by
biological reducing agents to release their loaded cargo in a controlled fashion, it is also
interesting to explore other types of cross-linkers that repond to various external stimuli
such as pH, enzymes, and proteins.

Figure 5.2: The polymer structures and cross-linked nanogels with modified crosslinkers.
To accomplish this, we hypothesize that if the cross-linking reaction occurs
during the aggregation of amphiphilic polymers, then it would facilitate the nanogel
formation and also provide lipophilic encapsulation in aqueous medium. To test this
concept, the designed amphiphilic polymers will consist of the reactive ester groups that
can be easily replaced by the cross-linker containing diamine functionalities. The crosslinking reaction will take place during the polymer aggregation. Using this concept, we
can introduce various types of cross-linkers in the nanogel scaffolds. Two polymer
systems are currently investigated in our research group.
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In the first design, we chose N-hydroxysuccinimide (NHS) as the reactive esters
to be incoported on the polymer pruecusors. We synthesized the amphiphilic ramdom
copolymers containing 30% PEG, 60% NHS, and 10% of PDS groups. The polymer
structure is shown in Figure 5.2. After initiating the nanogel formation with small
amount of disulfide cross-linking reaction, the diamino cross-linker will be added to
react with NHS groups to generate fully cross-linked polymer nanogels. By this
methodology, we can incorporate various types of cross-linkers containing diamine
functionalities for specific targeted external stimulus. We are currently optimizing this
system with acetal cross-linker containing diamines to prepare cross-linked nanogels
that respond to acidic condition.
In the second design, the pentafluorophenyl (PFP) ester will be used as an
activated ester which is known to be replaced with amines with great fidelity. While the
reactivity of PFP with amines is similar to the known NSH ester, it provides more
hydrophobicity rendering the polymer precursors to form a stable aggregation without
using initial disulfide bonds.

Figure 5.3: The PEG-PFP polymer structure and cystamine cross-linked nanogels.
In this design, we synthesize a random copolymer comprising PEG and PFP
units as illustrated in Figure 5.3. While the PEG groups are charge neutral water soluble
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units, PFPs are hydrophobic groups providing lipophilic encapsulation and are also
reactive towards cross-linking amine groups. The addition of the cross-linker containing
diamines to the stable polymer aggregation would result in stable cross-linked polymer
nanogels. We are currently studying this system with cystamine and alkyldiamine crosslinkers. Initial findings indicate that the PEG-PFP polymers form stable self- assembies
and provide lipophilic encapsulation. We are able to cross-link them with cystamine and
alkyldiamine cross-linkers affording highly stable cross-linked polymer nanogels. We
will ultilize this method to incorporate other cross-linker containing diamine units.

5.3 Summary
In this chapter, we summarize the key points detailed in each chapter and
present the ongoing work in our laboratory on the self-cross-linked polymer nanogels.
We hope that the findings of this dissertation on the new class of self-cross-linked
polymer nanogels provide insights for the development of effective nanoscopic drug
delivery vehicles with high stability of non-covalent lipophilic drug encapsulation.
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